Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF-kappa	B-protein
B	I-protein
-like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	B-cell_type
cells	I-cell_type
.	O

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

PLB-985	B-cell_line
cells	I-cell_line
represent	O
a	O
bipotential	B-cell_line
myelomonoblastic	I-cell_line
cell	I-cell_line
population	I-cell_line
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	B-protein
on	O
the	O
cell	O
surface	O
,	O
PLB-985	B-cell_line
cells	I-cell_line
were	O
chronically	O
infected	O
with	O
HIV-1	O
strain	O
IIIB	O
.	O

PLB-IIIB	B-cell_line
cells	I-cell_line
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	B-cell_type
myeloblasts	I-cell_type
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid-specific	B-protein
surface	I-protein
markers	I-protein
,	O
and	O
transcription	O
of	O
the	O
c-fms	B-DNA
proto-oncogene	I-DNA
.	O

NF-kappa	B-protein
B	I-protein
binding	O
activity	O
was	O
inducible	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB-985	B-cell_line
.	O

However	O
,	O
in	O
PLB-IIIB	B-cell_line
cells	I-cell_line
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O

These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	B-DNA
NF-kappa	I-DNA
B	I-DNA
site	I-DNA
from	O
the	O
interferon	B-DNA
beta	I-DNA
(	I-DNA
IFN-beta	I-DNA
)	I-DNA
promoter	I-DNA
.	O

Mutations	O
affecting	O
the	O
5	B-DNA
'	I-DNA
guanine	I-DNA
residues	I-DNA
of	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
were	O
unable	O
to	O
compete	O
for	O
these	O
NF-kappa	B-protein
B-related	I-protein
proteins	I-protein
.	O

Inducibility	O
of	O
endogenous	O
IFN-beta	B-RNA
and	I-RNA
IFN-alpha	I-RNA
RNA	I-RNA
was	O
also	O
increased	O
in	O
PLB-IIIB	B-cell_line
cells	I-cell_line
.	O

These	O
studies	O
indicate	O
that	O
HIV-1	O
infection	O
of	O
myelomonoblastic	B-cell_type
cells	I-cell_type
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF-kappa	B-protein
B	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
may	O
contribute	O
to	O
differential	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
expression	O
.	O

Induction	NULL
of	NULL
Monocytic	NULL
Differentiation	NULL
and	NULL
NF-	NULL
«	NULL
B-like	NULL
Activities	NULL
by	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
1	NULL
Infection	NULL
of	NULL
Myelomonoblastic	NULL
Cells	NULL
By	NULL
Anne	NULL
Roulston	NULL
,	NULL
``	NULL
S	NULL
!	NULL

Mario	NULL
D'Addario	NULL
,	NULL
``	NULL
$	NULL
!	NULL

Francois	NULL
Boulerice	NULL
,	NULL
*	NULL
!	NULL

Stephen	NULL
Caplan	NULL
,	NULL
t	NULL
!	NULL

l	NULL
Mark	NULL
A.	NULL
Wainberg	NULL
,	NULL
*8	NULL
!	NULL

%	NULL
and	NULL
John	NULL
Hiscott	NULL
*S	NULL
``	NULL
From	NULL
the	NULL
*Lady	NULL
Davis	NULL
Institute	NULL
for	NULL
Medical	NULL
Research	NULL
;	NULL
the	NULL
*Departments	NULL
of	NULL
Hematology	NULL
,	NULL
SMicrobiology	NULL
,	NULL
and	NULL
Medicine	NULL
,	NULL
Sir	NULL
Mortimer	NULL
B.	NULL
Davis-Jewish	NULL
General	NULL
Hospital	NULL
;	NULL
and	NULL
the	NULL
McGill	NULL
AIDS	NULL
Centre	NULL
McGill	NULL
University	NULL
,	NULL
Montreal	NULL
H3T	NULL
1E2	NULL
,	NULL
Quebec	NULL
,	NULL
Canada	NULL
Summary	NULL
The	NULL
effects	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
infection	NULL
on	NULL
cellular	NULL
differentiation	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
have	NULL
been	NULL
investigated	NULL
in	NULL
a	NULL
new	NULL
model	NULL
of	NULL
myeloid	NULL
differentiation	NULL
.	NULL

PLB-985	NULL
cells	NULL
represent	NULL
a	NULL
bipotential	NULL
myelomonoblastic	NULL
cell	NULL
population	NULL
capable	NULL
of	NULL
either	NULL
granulocytic	NULL
or	NULL
monocytic	NULL
differentiation	NULL
after	NULL
induction	NULL
with	NULL
appropriate	NULL
inducers	NULL
.	NULL

By	NULL
virtue	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
CD4	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
,	NULL
PLB-985	NULL
cells	NULL
were	NULL
chronically	NULL
infected	NULL
with	NULL
HIV-1	NULL
strain	NULL
IIIB	NULL
.	NULL

PLB-THB	NULL
cells	NULL
clearly	NULL
possessed	NULL
a	NULL
more	NULL
monocytic	NULL
phenotype	NULL
than	NULL
the	NULL
parental	NULL
myeloblasts	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
differential	NULL
staining	NULL
,	NULL
increased	NULL
expression	NULL
of	NULL
the	NULL
myeloid-specific	NULL
surface	NULL
markers	NULL
,	NULL
and	NULL
transcription	NULL
of	NULL
the	NULL
c-fms	NULL
proto-oncogene	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
was	NULL
inducible	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
in	NULL
PLB-985	NULL
.	NULL

However	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
constitutive	NULL
expression	NULL
of	NULL
a	NULL
novel	NULL
NF-KB	NULL
complex	NULL
was	NULL
detected	NULL
,	NULL
composed	NULL
of	NULL
proteins	NULL
ranging	NULL
between	NULL
70	NULL
and	NULL
110	NULL
kD	NULL
.	NULL

These	NULL
proteins	NULL
interacted	NULL
specifically	NULL
with	NULL
the	NULL
symmetric	NULL
NF-KB	NULL
site	NULL
from	NULL
the	NULL
interferon	NULL
3	NULL
(	NULL
IFN-	NULL
)	NULL
promoter	NULL
.	NULL

Mutations	NULL
affecting	NULL
the	NULL
5	NULL
``	NULL
guanine	NULL
residues	NULL
of	NULL
the	NULL
KB	NULL
site	NULL
were	NULL
unable	NULL
to	NULL
compete	NULL
for	NULL
these	NULL
NF-	NULL
«	NULL
B-related	NULL
proteins	NULL
.	NULL

Inducibility	NULL
of	NULL
endogenous	NULL
IFN-B	NULL
and	NULL
IFN-	NULL
RNA	NULL
was	NULL
also	NULL
increased	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

These	NULL
studies	NULL
indicate	NULL
that	NULL
HIV-1	NULL
infection	NULL
of	NULL
myelomonoblastic	NULL
cells	NULL
may	NULL
select	NULL
for	NULL
a	NULL
more	NULL
mature	NULL
monocytic	NULL
phenotype	NULL
and	NULL
that	NULL
unique	NULL
subunit	NULL
associations	NULL
of	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
proteins	NULL
may	NULL
contribute	NULL
to	NULL
differential	NULL
NF-	NULL
«	NULL
B-mediated	NULL
gene	NULL
expression	NULL
.	NULL

he	NULL
host	NULL
range	NULL
of	NULL
the	NULL
HIV-1	NULL
includes	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
CD4+*	NULL
Th	NULL
lymphocyte	NULL
,	NULL
cells	NULL
of	NULL
the	NULL
monocyte/macro-phage	NULL
lineage	NULL
,	NULL
and	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

Whereas	NULL
Th	NULL
cells	NULL
are	NULL
ultimately	NULL
destroyed	NULL
by	NULL
HIV	NULL
infection	NULL
,	NULL
infection	NULL
of	NULL
monocytic	NULL
cells	NULL
is	NULL
not	NULL
cytolytic	NULL
,	NULL
and	NULL
these	NULL
cells	NULL
may	NULL
act	NULL
as	NULL
reservoirs	NULL
for	NULL
viruses	NULL
,	NULL
thus	NULL
contributing	NULL
to	NULL
virus	NULL
spread	NULL
to	NULL
peripheral	NULL
tissues	NULL
including	NULL
the	NULL
lungs	NULL
,	NULL
brain	NULL
,	NULL
skin	NULL
,	NULL
and	NULL
lymph	NULL
nodes	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
HIV	NULL
infection	NULL
of	NULL
myeloid	NULL
cells	NULL
results	NULL
in	NULL
the	NULL
impairment	NULL
of	NULL
crucial	NULL
functions	NULL
involved	NULL
in	NULL
host	NULL
defense	NULL
,	NULL
such	NULL
as	NULL
antigen	NULL
presentation	NULL
,	NULL
chemo-taxis	NULL
,	NULL
cell	NULL
killing	NULL
,	NULL
and	NULL
cytokine	NULL
release	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

HIV-1	NULL
infection	NULL
of	NULL
PBMC	NULL
and	NULL
monocytes/macrophages	NULL
may	NULL
have	NULL
a	NULL
dramatic	NULL
impact	NULL
on	NULL
cellular	NULL
gene	NULL
expression	NULL
and	NULL
in	NULL
particular	NULL
on	NULL
cytokine	NULL
production	NULL
(	NULL
7-17	NULL
)	NULL
.	NULL

HIV	NULL
infection	NULL
does	NULL
not	NULL
generally	NULL
lead	NULL
to	NULL
constitutive	NULL
cytokine	NULL
gene	NULL
transcription	NULL
and	NULL
secretion	NULL
(	NULL
9	NULL
,	NULL
12	NULL
,	NULL
13	NULL
)	NULL
;	NULL
however	NULL
,	NULL
the	NULL
cytokine	NULL
response	NULL
of	NULL
HIV-infected	NULL
cells	NULL
to	NULL
subsequent	NULL
antigenic	NULL
challenge	NULL
by	NULL
viruses	NULL
,	NULL
lipopolysaccharides	NULL
,	NULL
or	NULL
poly	NULL
(	NULL
I	NULL
:	NULL
C	NULL
)	NULL
can	NULL
be	NULL
affected	NULL
in	NULL
1	NULL
A.	NULL
Roulston	NULL
and	NULL
M.	NULL
D'Addario	NULL
were	NULL
equal	NULL
contributors	NULL
to	NULL
this	NULL
work	NULL
.	NULL

HIV-infected	NULL
cultures	NULL
,	NULL
often	NULL
leading	NULL
to	NULL
increased	NULL
expression	NULL
of	NULL
TNF	NULL
and	NULL
IL-1	NULL
(	NULL
9	NULL
,	NULL
12	NULL
,	NULL
15-17	NULL
)	NULL
.	NULL

Cytokine	NULL
release	NULL
by	NULL
HIV-infected	NULL
cells	NULL
may	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
alter	NULL
the	NULL
course	NULL
of	NULL
virus	NULL
pathogenesis	NULL
in	NULL
vitro	NULL
.	NULL

For	NULL
example	NULL
,	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
TNF-	NULL
,	NULL
IL-1	NULL
,	NULL
or	NULL
GM-CSF	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
increase	NULL
gene	NULL
expression	NULL
driven	NULL
by	NULL
the	NULL
HIV-1	NULL
LTR	NULL
in	NULL
transfection	NULL
studies	NULL
,	NULL
and	NULL
to	NULL
stimulate	NULL
virus	NULL
multiplication	NULL
in	NULL
vitro	NULL
(	NULL
10	NULL
,	NULL
11	NULL
,	NULL
18-21	NULL
)	NULL
.	NULL

Cytokines	NULL
,	NULL
phorbol	NULL
esters	NULL
,	NULL
virus	NULL
infections	NULL
,	NULL
double-stranded	NULL
RNA	NULL
,	NULL
and	NULL
other	NULL
mitogenic	NULL
agents	NULL
potentiate	NULL
HIV	NULL
replica-tion	NULL
,	NULL
in	NULL
part	NULL
via	NULL
activation	NULL
of	NULL
NF-KB	NULL
,	NULL
a	NULL
family	NULL
of	NULL
mitogen-and	NULL
phorbol-ester-inducible	NULL
DNA	NULL
binding	NULL
transcription	NULL
factors	NULL
which	NULL
bind	NULL
to	NULL
and	NULL
activate	NULL
the	NULL
HIV	NULL
enhancer	NULL
(	NULL
22-24	NULL
)	NULL
.	NULL

NF-KB	NULL
proteins	NULL
bind	NULL
to	NULL
a	NULL
decameric	NULL
recognition	NULL
sequence	NULL
(	NULL
con-sensus	NULL
5-GGGRNNYYCC-3	NULL
'	NULL
)	NULL
present	NULL
in	NULL
the	NULL
promoter	NULL
regions	NULL
of	NULL
many	NULL
cellular	NULL
genes	NULL
encoding	NULL
immunoregulatory	NULL
molecules	NULL
(	NULL
II-2	NULL
receptor-	NULL
,	NULL
MHC	NULL
class	NULL
I	NULL
antigens	NULL
,	NULL
and	NULL
TNF	NULL
receptor	NULL
)	NULL
and	NULL
cytokines	NULL
(	NULL
II	NULL
>	NULL
2	NULL
,	NULL
IL-6	NULL
,	NULL
IL-8	NULL
,	NULL
IFN-	NULL
,	NULL
TNF	NULL
,	NULL
and	NULL
GM-CSF	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
enhancer	NULL
domains	NULL
of	NULL
several	NULL
viruses	NULL
(	NULL
22	NULL
)	NULL
.	NULL

To	NULL
date	NULL
,	NULL
NF-KB	NULL
induction	NULL
has	NULL
been	NULL
characterized	NULL
predominantly	NULL
as	NULL
a	NULL
posttranslational	NULL
event	NULL
.	NULL

Latent	NULL
NF-KB	NULL
exists	NULL
in	NULL
the	NULL
cytoplasm	NULL
as	NULL
a	NULL
heterotrimeric	NULL
protein	NULL
;	NULL
induction	NULL
in	NULL
751	NULL
-	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
Rockefeller	NULL
University	NULL
Press	NULL
»	NULL
«	NULL
0022-1007/92/03/0751/13	NULL
$	NULL
2.00	NULL
Volume	NULL
175	NULL
March	NULL
1992	NULL
751-763	NULL
volves	NULL
the	NULL
dissociation	NULL
of	NULL
a	NULL
p65-p50	NULL
heterodimer	NULL
from	NULL
a	NULL
regulatory	NULL
protein	NULL
(	NULL
inhibitor	NULL
of	NULL
«	NULL
B	NULL
or	NULL
IxB	NULL
)	NULL
,	NULL
and	NULL
nuclear	NULL
transloca-tion	NULL
of	NULL
the	NULL
DNA-binding	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
(	NULL
22	NULL
,	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
IKB	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
necessary	NULL
requirement	NULL
for	NULL
dissociation	NULL
of	NULL
the	NULL
heterotrimeric	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Recent	NULL
cloning	NULL
of	NULL
the	NULL
p65	NULL
and	NULL
p50	NULL
subunits	NULL
has	NULL
revealed	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
region	NULL
of	NULL
both	NULL
proteins	NULL
shares	NULL
homology	NULL
with	NULL
the	NULL
c-rel	NULL
proto-oncogene	NULL
,	NULL
(	NULL
27-32	NULL
)	NULL
.	NULL

Furthermore	NULL
these	NULL
studies	NULL
indicate	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
may	NULL
also	NULL
be	NULL
controlled	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
.	NULL

As	NULL
a	NULL
step	NULL
toward	NULL
understanding	NULL
the	NULL
consequences	NULL
of	NULL
HIV-1	NULL
infection	NULL
on	NULL
myeloid	NULL
differentiation	NULL
and	NULL
cellular	NULL
gene	NULL
expression	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
induction	NULL
of	NULL
monocytic	NULL
differentiation	NULL
and	NULL
NF-	NULL
«	NULL
B/rel	NULL
activities	NULL
in	NULL
a	NULL
new	NULL
myelomonoblastic	NULL
model	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

PLB-985	NULL
cells	NULL
represent	NULL
an	NULL
immature	NULL
blast	NULL
population	NULL
,	NULL
capable	NULL
of	NULL
both	NULL
monocytic	NULL
and	NULL
granulocytic	NULL
differentiation	NULL
(	NULL
33	NULL
)	NULL
.	NULL

By	NULL
virtue	NULL
of	NULL
CD4	NULL
expression	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
,	NULL
these	NULL
cells	NULL
were	NULL
infected	NULL
by	NULL
HIV-1	NULL
strain	NULL
IIIB	NULL
and	NULL
a	NULL
chronically	NULL
infected	NULL
line	NULL
(	NULL
PLB-IIIB	NULL
)	NULL
was	NULL
established	NULL
.	NULL

Characterization	NULL
of	NULL
PLB-IIIB	NULL
cells	NULL
and	NULL
NF-	NULL
«	NULL
B-related	NULL
activity	NULL
has	NULL
demonstrated	NULL
that	NULL
HIV-1	NULL
infection	NULL
of	NULL
myelomonoblastic	NULL
cells	NULL
may	NULL
select	NULL
for	NULL
a	NULL
more	NULL
mature	NULL
monocytic	NULL
phenotype	NULL
,	NULL
and	NULL
that	NULL
distinct	NULL
subunit	NULL
associations	NULL
of	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
proteins	NULL
may	NULL
contribute	NULL
to	NULL
developmental	NULL
and	NULL
inducible	NULL
NF-KB-mediated	NULL
gene	NULL
expression	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
Culture	NULL
Myelomonoblastic	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
were	NULL
maintained	NULL
at	NULL
37°C	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
,	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Gibco	NULL
Laboratories	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
1	NULL
%	NULL
glutamine	NULL
,	NULL
1,000	NULL
IU/ml	NULL
penicillin	NULL
,	NULL
20	NULL
ug/ml	NULL
streptomycin	NULL
,	NULL
and	NULL
1	NULL
ug/ml	NULL
gen-tamycin	NULL
.	NULL

Induction	NULL
of	NULL
exponentially	NULL
growing	NULL
cells	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
for	NULL
the	NULL
individual	NULL
experiments	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
25	NULL
ng/ml	NULL
,	NULL
DMSO	NULL
(	NULL
Aldrich	NULL
Chemical	NULL
Co.	NULL
)	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1.25	NULL
%	NULL
,	NULL
2'-dibutyryl	NULL
adenosine-3	NULL
'	NULL
,	NULL
5	NULL
``	NULL
-cyclic	NULL
monophos-phate	NULL
(	NULL
Bt2cAMP	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
750	NULL
uM	NULL
,	NULL
cis-retinoic	NULL
acid	NULL
(	NULL
RA	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
uM	NULL
,	NULL
and	NULL
TNF-a	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
100	NULL
U/ml	NULL
.	NULL

Infection	NULL
of	NULL
PLB-985	NULL
Cells	NULL
were	NULL
infected	NULL
using	NULL
supernatant	NULL
HTLV-IIIB	NULL
virus	NULL
obtained	NULL
from	NULL
U9-IIIB	NULL
cells	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
34	NULL
)	NULL
.	NULL

P24	NULL
Antigen	NULL
Determination	NULL
Immunofluorescence	NULL
.	NULL

-	NULL
Production	NULL
of	NULL
HIV-1-specific	NULL
p24	NULL
antigen	NULL
was	NULL
monitored	NULL
over	NULL
a	NULL
period	NULL
of	NULL
60	NULL
d	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
.	NULL

Cells	NULL
were	NULL
fixed	NULL
on	NULL
multibeveled	NULL
slides	NULL
with	NULL
methanol/ace-tone	NULL
(	NULL
1:1	NULL
)	NULL
.	NULL

An	NULL
aliquot	NULL
of	NULL
mouse	NULL
anti-p24	NULL
antibody	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
R.	NULL
Gallo	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
diluted	NULL
1:1,000	NULL
in	NULL
PBS	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
for	NULL
30	NULL
min	NULL
.	NULL

After	NULL
washing	NULL
with	NULL
PBS	NULL
,	NULL
goat	NULL
anti-mouse-conjugated	NULL
FITC	NULL
antibody	NULL
(	NULL
diluted	NULL
1:1,000	NULL
in	NULL
PBS	NULL
)	NULL
(	NULL
Caltag	NULL
Laboratories	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
was	NULL
added	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Slides	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
plus	NULL
0.25	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
air-dried	NULL
,	NULL
and	NULL
mounted	NULL
with	NULL
glycerol	NULL
.	NULL

ELISA	NULL
.	NULL

-	NULL
An	NULL
ELISA	NULL
(	NULL
Abbott	NULL
Labs	NULL
,	NULL
North	NULL
Chicago	NULL
,	NULL
IL	NULL
)	NULL
was	NULL
used	NULL
to	NULL
detect	NULL
HIV-1	NULL
p24	NULL
in	NULL
culture	NULL
fluids	NULL
,	NULL
as	NULL
per	NULL
manufacturer	NULL
's	NULL
in-structions	NULL
.	NULL

Reverse	NULL
Transcriptase	NULL
Analysis	NULL
At	NULL
different	NULL
time	NULL
points	NULL
after	NULL
infection	NULL
1	NULL
ml	NULL
of	NULL
culture	NULL
medium	NULL
was	NULL
centrifuged	NULL
at	NULL
1,200	NULL
rpm	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Reverse	NULL
transcriptase	NULL
activity	NULL
was	NULL
evaluated	NULL
without	NULL
further	NULL
virus	NULL
concentration	NULL
using	NULL
'	NULL
H	NULL
TTP	NULL
incorporation	NULL
into	NULL
acid-precipitable	NULL
nucleic	NULL
acid	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
RNA	NULL
Total	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
untreated	NULL
and	NULL
PMA-treated	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
at	NULL
specific	NULL
times	NULL
using	NULL
a	NULL
modified	NULL
guanidinium	NULL
isothiocyanate	NULL
procedure	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Total	NULL
RNA	NULL
(	NULL
20	NULL
pug	NULL
)	NULL
was	NULL
electrophoresed	NULL
in	NULL
a	NULL
1	NULL
%	NULL
denaturing	NULL
formaldehyde	NULL
gel	NULL
,	NULL
transferred	NULL
to	NULL
a	NULL
nylon	NULL
membrane	NULL
,	NULL
and	NULL
hybridized	NULL
with	NULL
-	NULL
[	NULL
``	NULL
P	NULL
]	NULL
ATP	NULL
nick	NULL
translated	NULL
probes	NULL
at	NULL
42°C	NULL
.	NULL

The	NULL
probes	NULL
include	NULL
a	NULL
1.23-kb	NULL
c-fms	NULL
fragment	NULL
generated	NULL
by	NULL
EcoRI	NULL
cleavage	NULL
of	NULL
clone	NULL
pc-fms	NULL
104	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
a	NULL
1.1-kb	NULL
B-actin	NULL
frag-ment	NULL
,	NULL
a	NULL
4.5-kb	NULL
c-myc	NULL
fragment	NULL
containing	NULL
exons	NULL
2	NULL
and	NULL
3	NULL
produced	NULL
by	NULL
cleavage	NULL
of	NULL
plasmid	NULL
pHSR-1	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collec-tion	NULL
)	NULL
with	NULL
Xbal	NULL
,	NULL
EcoRI	NULL
,	NULL
and	NULL
HB10	NULL
,	NULL
a	NULL
12.5-kb	NULL
HIV-IIIB	NULL
probe	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
University	NULL
of	NULL
California	NULL
at	NULL
San	NULL
Diego	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
washed	NULL
at	NULL
55-60°C	NULL
,	NULL
air-dried	NULL
,	NULL
and	NULL
exposed	NULL
to	NULL
X-OMAT	NULL
film	NULL
(	NULL
Kodak	NULL
)	NULL
at	NULL
-70°C	NULL
.	NULL

The	NULL
relative	NULL
amounts	NULL
of	NULL
each	NULL
signal	NULL
were	NULL
quantified	NULL
by	NULL
laser	NULL
densitometry	NULL
(	NULL
Ultrascan	NULL
XL	NULL
;	NULL
Pharmacia	NULL
LKB	NULL
Biotechnology	NULL
Inc.	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
Surface	NULL
Markers	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
or	NULL
retinoic	NULL
acid	NULL
were	NULL
analyzed	NULL
for	NULL
expression	NULL
of	NULL
myeloid	NULL
specific	NULL
surface	NULL
markers	NULL
using	NULL
mAbs	NULL
directed	NULL
against	NULL
CD13	NULL
,	NULL
CD14	NULL
,	NULL
CD33	NULL
,	NULL
CD34	NULL
,	NULL
and	NULL
CD67	NULL
and	NULL
analyzed	NULL
in	NULL
an	NULL
Epics	NULL
Profile	NULL
II	NULL
cytofluorograph	NULL
;	NULL
(	NULL
Coulter	NULL
Electronics	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

Whole	NULL
Cell	NULL
Extract	NULL
Preparations	NULL
Whole	NULL
cell	NULL
extracts	NULL
(	NULL
WCE	NULL
)	NULL
were	NULL
prepared	NULL
from	NULL
untreated	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
or	NULL
from	NULL
cells	NULL
treated	NULL
for	NULL
6	NULL
or	NULL
15	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
25	NULL
ng/ml	NULL
)	NULL
or	NULL
TNF-a	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Gel	NULL
Retardation	NULL
Assays	NULL
Cell	NULL
protein	NULL
in	NULL
WCE	NULL
buffer	NULL
(	NULL
0.1	NULL
M	NULL
KCI	NULL
)	NULL
,	NULL
was	NULL
preincubated	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI	NULL
:	NULL
dC	NULL
)	NULL
as	NULL
nonspecific	NULL
competitor	NULL
DNA	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

P-labeled	NULL
probe	NULL
(	NULL
0.2	NULL
ng	NULL
)	NULL
consisting	NULL
of	NULL
the	NULL
P2	NULL
oligonucleotide	NULL
(	NULL
5-GGGAAATTCCGGGAAATTCC-3	NULL
'	NULL
)	NULL
or	NULL
the	NULL
HIV	NULL
enhancer	NULL
(	NULL
5'-AGGGACTTTCCGCTGGGGACTTTCC-3	NULL
``	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
protein	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Competition	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
incubating	NULL
125-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
competitor	NULL
(	NULL
25	NULL
ng	NULL
)	NULL
with	NULL
the	NULL
protein	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
radiolabeled	NULL
probe	NULL
.	NULL

UV	NULL
Crosslinking	NULL
Analysis	NULL
For	NULL
UV	NULL
crosslinking	NULL
analysis	NULL
,	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
double-stranded	NULL
BUdR-substituted	NULL
**P-labeled	NULL
P2	NULL
or	NULL
HIV	NULL
oligonucleotide	NULL
probes	NULL
.	NULL

The	NULL
crosslinking	NULL
procedure	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
36	NULL
)	NULL
.	NULL

2	NULL
Abbreviation	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
WCE	NULL
,	NULL
whole	NULL
cell	NULL
extract	NULL
(	NULL
s	NULL
)	NULL
.	NULL

752	NULL
NF-	NULL
«	NULL
B	NULL
Activity	NULL
in	NULL
HIV-1-infected	NULL
Monocytic	NULL
Cells	NULL
Analysis	NULL
of	NULL
IFN	NULL
RNA	NULL
Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
uninduced	NULL
or	NULL
Sendai	NULL
virus-induced	NULL
PLB-985	NULL
or	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
IFN-	NULL
primed	NULL
(	NULL
250	NULL
U/ml	NULL
)	NULL
,	NULL
then	NULL
treated	NULL
with	NULL
Sendai	NULL
virus	NULL
(	NULL
2,000	NULL
HAU/ml	NULL
)	NULL
for	NULL
6	NULL
h	NULL
before	NULL
RNA	NULL
isolation	NULL
.	NULL

IFN-	NULL
and	NULL
IFN-B-specific	NULL
RNA	NULL
was	NULL
analyzed	NULL
by	NULL
PCR-mediated	NULL
RNA	NULL
phenotyping	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
9	NULL
)	NULL
using	NULL
the	NULL
IFN-ax	NULL
(	NULL
sense	NULL
:	NULL
5-CAATATCTACGATGGCTTCGC-3	NULL
'	NULL
and	NULL
antisense	NULL
5'CAGAAGGCTCCAGCCATCTCT-3	NULL
'	NULL
)	NULL
and	NULL
IFN-§	NULL
primers	NULL
described	NULL
previously	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Results	NULL
Isolation	NULL
and	NULL
Characterization	NULL
of	NULL
PLB-IIIB	NULL
Cells	NULL
.	NULL

PLB-985	NULL
cells	NULL
were	NULL
originally	NULL
derived	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
acute	NULL
non-lymphocytic	NULL
leukemia	NULL
and	NULL
characterized	NULL
as	NULL
a	NULL
diploid	NULL
myelomonoblastic	NULL
cell	NULL
line	NULL
(	NULL
33	NULL
)	NULL
.	NULL

PLB-985	NULL
cells	NULL
are	NULL
capable	NULL
of	NULL
differentiation	NULL
along	NULL
the	NULL
monocytic	NULL
lineage	NULL
after	NULL
treatment	NULL
with	NULL
phorbol	NULL
esters	NULL
or	NULL
along	NULL
the	NULL
granulocytic	NULL
lineage	NULL
after	NULL
treatment	NULL
with	NULL
agents	NULL
such	NULL
as	NULL
DMSO	NULL
,	NULL
dibutyryl	NULL
cAMP	NULL
,	NULL
or	NULL
retinoic	NULL
acid	NULL
(	NULL
33	NULL
)	NULL
.	NULL

By	NULL
virtue	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
CD4	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
>	NULL
99	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
,	NULL
PLB-985	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HIV-IIIB	NULL
using	NULL
culture	NULL
fluids	NULL
of	NULL
HIV-1-infected	NULL
U937	NULL
cells	NULL
(	NULL
34	NULL
)	NULL
.	NULL

At	NULL
various	NULL
times	NULL
after	NULL
infection	NULL
,	NULL
the	NULL
cells	NULL
and/or	NULL
culture	NULL
fluids	NULL
were	NULL
assayed	NULL
for	NULL
RT	NULL
activity	NULL
,	NULL
p24	NULL
core	NULL
antigen	NULL
,	NULL
and	NULL
accumulation	NULL
of	NULL
viral	NULL
RNA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

After	NULL
a	NULL
lag	NULL
period	NULL
of	NULL
about	NULL
10	NULL
d	NULL
,	NULL
the	NULL
number	NULL
of	NULL
p24-positive	NULL
cells	NULL
increased	NULL
rapidly	NULL
together	NULL
with	NULL
levels	NULL
of	NULL
RT	NULL
.	NULL

By	NULL
day	NULL
18	NULL
,	NULL
more	NULL
than	NULL
50	NULL
%	NULL
of	NULL
the	NULL
population	NULL
was	NULL
infected	NULL
with	NULL
HIV-1	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
.	NULL

Spliced	NULL
and	NULL
unspliced	NULL
viral	NULL
RNA	NULL
species	NULL
were	NULL
easily	NULL
detectable	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
using	NULL
the	NULL
HB1O0	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

During	NULL
the	NULL
next	NULL
several	NULL
weeks	NULL
,	NULL
the	NULL
infected	NULL
cell	NULL
population	NULL
underwent	NULL
considerable	NULL
death	NULL
,	NULL
presumably	NULL
because	NULL
of	NULL
rapid	NULL
virus	NULL
multiplication	NULL
.	NULL

Within	NULL
2	NULL
mo	NULL
,	NULL
a	NULL
chronically	NULL
infected	NULL
cell	NULL
population	NULL
(	NULL
>	NULL
95	NULL
%	NULL
positive	NULL
for	NULL
p24	NULL
antigen	NULL
and	NULL
<	NULL
4	NULL
%	NULL
CD4*	NULL
)	NULL
emerged	NULL
that	NULL
possessed	NULL
a	NULL
more	NULL
mature	NULL
monocytic	NULL
phenotype	NULL
than	NULL
the	NULL
immature	NULL
parental	NULL
blast	NULL
cells	NULL
(	NULL
compare	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
A	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Phorbol	NULL
ester	NULL
treatment	NULL
of	NULL
PLB-985	NULL
produced	NULL
an	NULL
adherent	NULL
,	NULL
monocyte-like	NULL
phenotype	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
PLB-IIIB	NULL
without	NULL
induction	NULL
displayed	NULL
several	NULL
characteristics	NULL
of	NULL
monocyte	NULL
maturation	NULL
,	NULL
including	NULL
less	NULL
basophilic	NULL
cytoplasm	NULL
,	NULL
decreased	NULL
nuclear/cytoplasmic	NULL
ratio	NULL
,	NULL
production	NULL
of	NULL
vacuoles	NULL
,	NULL
less	NULL
visible	NULL
nucleoli	NULL
,	NULL
ruffling	NULL
at	NULL
the	NULL
cytoplasmic	NULL
membrane	NULL
,	NULL
and	NULL
lobularization	NULL
of	NULL
the	NULL
nucleus	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
C	NULL
)	NULL
.	NULL

PMA	NULL
treatment	NULL
of	NULL
the	NULL
PLB-IIIB	NULL
cells	NULL
further	NULL
accentuated	NULL
these	NULL
features	NULL
of	NULL
the	NULL
monocytic	NULL
phenotype	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
D	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
Myeloid	NULL
Specific	NULL
Surface	NULL
Markers	NULL
.	NULL

To	NULL
deter	NULL
A	NULL
B	NULL
1	NULL
-	NULL
2	NULL
60	NULL
500000	NULL
|-	NULL
40	NULL
w	NULL
0000	NULL
aut	NULL
-	NULL
9.2	NULL
kB	NULL
ed	NULL
>	NULL
a	NULL
o	NULL
x	NULL
3	NULL
|-	NULL
300000	NULL
3	NULL
3	NULL
|-	NULL
200000	NULL
|-a	NULL
.	NULL

[	NULL
aet	NULL
g	NULL
;	NULL
<	NULL
a	NULL
~-	NULL
4.5kB	NULL
a	NULL
|-	NULL
100000	NULL
a	NULL
0	NULL
20	NULL
Time	NULL
(	NULL
days	NULL
after	NULL
infection	NULL
)	NULL
Figure	NULL
1	NULL
.	NULL

-	NULL
2.0kB	NULL
Kinetics	NULL
of	NULL
infection	NULL
of	NULL
PLB-985	NULL
cells	NULL
by	NULL
HIV-1	NULL
.	NULL

(	NULL
4	NULL
)	NULL
The	NULL
kinetics	NULL
of	NULL
infection	NULL
were	NULL
assessed	NULL
by	NULL
p24	NULL
core	NULL
antigen	NULL
immunofluorescence	NULL
(	NULL
M	NULL
)	NULL
and	NULL
by	NULL
analysis	NULL
of	NULL
reverse	NULL
transcriptase	NULL
activity	NULL
(	NULL
OQ	NULL
)	NULL
in	NULL
culture	NULL
supernatants	NULL
at	NULL
various	NULL
times	NULL
after	NULL
initial	NULL
infection	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Detection	NULL
of	NULL
HIV-1	NULL
viral	NULL
RNA	NULL
species	NULL
in	NULL
chronically	NULL
infected	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

Total	NULL
RNA	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
from	NULL
PLB-985	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and/or	NULL
PLB-IIIB	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
was	NULL
electrophoresed	NULL
in	NULL
a	NULL
1	NULL
%	NULL
formaldehyde	NULL
gel	NULL
,	NULL
transferred	NULL
to	NULL
a	NULL
nylon	NULL
filter	NULL
(	NULL
Amersham	NULL
Corp.	NULL
)	NULL
,	NULL
and	NULL
hybridized	NULL
with	NULL
the	NULL
HB10	NULL
probe	NULL
.	NULL

753	NULL
Roulston	NULL
et	NULL
al	NULL
.	NULL

Figure	NULL
2	NULL
.	NULL

-	NULL
Morphological	NULL
characteristics	NULL
of	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

PLB-985	NULL
cells	NULL
(	NULL
4	NULL
and	NULL
B	NULL
)	NULL
and	NULL
PLB-IIIB	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
were	NULL
fixed	NULL
and	NULL
differentially	NULL
stained	NULL
with	NULL
Giemsa	NULL
and	NULL
examined	NULL
by	NULL
phase	NULL
contrast	NULL
microscopy	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
untreated	NULL
(	NULL
A	NULL
and	NULL
C	NULL
)	NULL
or	NULL
PMA	NULL
treated	NULL
for	NULL
6	NULL
h	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
before	NULL
staining	NULL
.	NULL

mine	NULL
whether	NULL
the	NULL
morphological	NULL
alterations	NULL
were	NULL
accompanied	NULL
by	NULL
other	NULL
changes	NULL
in	NULL
the	NULL
PLB-IIIB	NULL
phenotype	NULL
,	NULL
expression	NULL
of	NULL
myeloid-specific	NULL
markers	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

PLB-985	NULL
cells	NULL
were	NULL
<	NULL
5	NULL
%	NULL
positive	NULL
for	NULL
the	NULL
monocyte-specific	NULL
marker	NULL
CD14	NULL
,	NULL
whereas	NULL
the	NULL
PLB-IIIB	NULL
cells	NULL
were	NULL
about	NULL
20	NULL
%	NULL
positive	NULL
for	NULL
the	NULL
monocyte-specific	NULL
CD14	NULL
surface	NULL
antigen	NULL
.	NULL

After	NULL
PMA	NULL
treatment	NULL
,	NULL
PLB-IIIB	NULL
cells	NULL
became	NULL
>	NULL
60	NULL
%	NULL
CD14	NULL
positive	NULL
within	NULL
24	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
other	NULL
myeloid	NULL
markers	NULL
CD13	NULL
,	NULL
CD33	NULL
,	NULL
and	NULL
CD67	NULL
remained	NULL
at	NULL
>	NULL
90	NULL
%	NULL
.	NULL

Similarly	NULL
5-15	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
CD34	NULL
positive	NULL
both	NULL
before	NULL
and	NULL
after	NULL
infection	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
c-fms	NULL
and	NULL
c-myc	NULL
Proto-oncogenes	NULL
.	NULL

-	NULL
Alteration	NULL
of	NULL
proto-oncogene	NULL
expression	NULL
is	NULL
a	NULL
recognized	NULL
consequence	NULL
of	NULL
induction	NULL
of	NULL
differentiation	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
hematopoietic	NULL
cell	NULL
types	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
effects	NULL
of	NULL
HIV-1	NULL
infection	NULL
on	NULL
PMA-induced	NULL
proto-oncogene	NULL
expression	NULL
,	NULL
the	NULL
steady	NULL
state	NULL
mRNA	NULL
levels	NULL
for	NULL
c-myc	NULL
and	NULL
c-fms	NULL
were	NULL
measured	NULL
at	NULL
different	NULL
times	NULL
after	NULL
PMA	NULL
treatment	NULL
of	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

In	NULL
both	NULL
cell	NULL
types	NULL
,	NULL
c-mys	NULL
RNA	NULL
levels	NULL
decreased	NULL
about	NULL
2-3	NULL
fold	NULL
by	NULL
24	NULL
h	NULL
after	NULL
PMA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
upper	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
c-fms	NULL
RNA	NULL
was	NULL
only	NULL
weakly	NULL
detectable	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
in	NULL
PLB-985	NULL
cells	NULL
before	NULL
or	NULL
after	NULL
PMA	NULL
induction	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
middle	NULL
,	NULL
lanes	NULL
1-5	NULL
)	NULL
.	NULL

In	NULL
untreated	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
c-fms	NULL
RNA	NULL
was	NULL
present	NULL
in	NULL
low	NULL
quantities	NULL
.	NULL

This	NULL
level	NULL
of	NULL
c-fms	NULL
was	NULL
induced	NULL
more	NULL
than	NULL
20-fold	NULL
by	NULL
PMA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
middle	NULL
,	NULL
lanes	NULL
6-10	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
B-actin	NULL
RNA	NULL
did	NULL
not	NULL
fluctuate	NULL
significantly	NULL
with	NULL
induction	NULL
or	NULL
differentiation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
bottom	NULL
)	NULL
.	NULL

After	NULL
granulocyte	NULL
induction	NULL
of	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
with	NULL
dibutyryl	NULL
cAMP	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
c-fms	NULL
was	NULL
observed	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
morphological	NULL
and	NULL
histochemical	NULL
studies	NULL
demonstrated	NULL
that	NULL
PLB-IIIB	NULL
cells	NULL
were	NULL
nonresponsive	NULL
to	NULL
inducers	NULL
of	NULL
granulocytic	NULL
differentiation	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
cell	NULL
population	NULL
had	NULL
irreversibly	NULL
differentiated	NULL
along	NULL
the	NULL
monocytic	NULL
lineage	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
NFB	NULL
Binding	NULL
Activity	NULL
in	NULL
PLB-IIIB	NULL
Cells	NULL
,	NULL
Previous	NULL
studies	NULL
have	NULL
demonstrated	NULL
a	NULL
correlation	NULL
between	NULL
monocyte	NULL
maturation	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
39-41	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
NF-KB	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
represent	NULL
a	NULL
family	NULL
of	NULL
rel-related	NULL
DNA	NULL
binding	NULL
proteins	NULL
involved	NULL
in	NULL
both	NULL
transcriptional	NULL
control	NULL
and	NULL
oncogen-esis	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
22	NULL
,	NULL
27-32	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
sought	NULL
to	NULL
examine	NULL
the	NULL
relationship	NULL
between	NULL
HIV	NULL
infection	NULL
,	NULL
monocytic	NULL
differentiation	NULL
,	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B/rel	NULL
transcription	NULL
complex	NULL
in	NULL
this	NULL
new	NULL
myelomonoblastic	NULL
model	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

Induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
examined	NULL
after	NULL
treatment	NULL
with	NULL
PMA	NULL
or	NULL
TNF-	NULL
,	NULL
using	NULL
754	NULL
NF-	NULL
«	NULL
B	NULL
Activity	NULL
in	NULL
HIV-1-infected	NULL
Monocytic	NULL
Cells	NULL
CD14	NULL
Expressing	NULL
Cel	NULL
©	NULL
“	NULL
I	NULL
...	NULL
é	NULL
S	NULL
-o-	NULL
-	NULL
-O	NULL
-	NULL
-o	NULL
0	NULL
-	NULL
-O-	NULL
~	NULL
2	NULL
6	NULL
12	NULL
Time	NULL
after	NULL
PMA	NULL
addition	NULL
(	NULL
hr	NULL
)	NULL
B	NULL
12G	NULL
)	NULL
é	NULL
80	NULL
&	NULL
g	NULL
a	NULL
60	NULL
a	NULL
40	NULL
M	NULL
Surface	NULL
Marker	NULL
Figure	NULL
3	NULL
.	NULL

-	NULL
Myeloid-specific	NULL
surface	NULL
marker	NULL
expression	NULL
.	NULL

PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
PMA	NULL
treated	NULL
for	NULL
various	NULL
times	NULL
before	NULL
surface	NULL
marker	NULL
analysis	NULL
using	NULL
the	NULL
EPICS	NULL
cytofluorograph	NULL
(	NULL
Coulter	NULL
Electronics	NULL
Inc.	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
percentage	NULL
of	NULL
CD14	NULL
positive	NULL
cells	NULL
is	NULL
plotted	NULL
as	NULL
a	NULL
function	NULL
of	NULL
time	NULL
after	NULL
PMA	NULL
treatment	NULL
.	NULL

(	NULL
@	NULL
)	NULL
PLB-IIIB	NULL
;	NULL
(	NULL
O	NULL
)	NULL
PLB-985	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
levels	NULL
of	NULL
CD13-	NULL
,	NULL
CD33-	NULL
,	NULL
and	NULL
CD34-positive	NULL
PLB-985	NULL
(	NULL
&	NULL
)	NULL
and	NULL
PLB-IIIB	NULL
(	NULL
WR	NULL
)	NULL
cells	NULL
.	NULL

the	NULL
P2	NULL
oligonucleotide	NULL
which	NULL
consists	NULL
of	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
NF-KB	NULL
site	NULL
found	NULL
in	NULL
IFN-	NULL
(	NULL
PRDII	NULL
site	NULL
,	NULL
-64	NULL
to	NULL
-55	NULL
)	NULL
and	NULL
human	NULL
c-rel	NULL
(	NULL
-28	NULL
to	NULL
-18	NULL
)	NULL
or	NULL
the	NULL
HIV	NULL
enhancer	NULL
oligonucleotide	NULL
which	NULL
contains	NULL
two	NULL
NF-	NULL
«	NULL
B-binding	NULL
sites	NULL
found	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
~105	NULL
to	NULL
-80	NULL
)	NULL
.	NULL

In	NULL
PLB-985	NULL
cells	NULL
,	NULL
multiple	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
induced	NULL
by	NULL
5	NULL
or	NULL
16	NULL
h	NULL
of	NULL
PMA	NULL
or	NULL
TNF	NULL
treatment	NULL
.	NULL

Both	NULL
inducers	NULL
appeared	NULL
to	NULL
be	NULL
equally	NULL
effective	NULL
in	NULL
stimulating	NULL
NF-	NULL
«	NULL
B-DNA	NULL
binding	NULL
activities	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
A	NULL
,	NULL
lanes	NULL
1-3	NULL
and	NULL
7-9	NULL
)	NULL
.	NULL

In	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
a	NULL
distinct	NULL
pattern	NULL
of	NULL
protein-DNA	NULL
complex	NULL
formation	NULL
(	NULL
complex	NULL
A	NULL
)	NULL
was	NULL
detected	NULL
consisting	NULL
of	NULL
strong	NULL
constitutive	NULL
P2	NULL
DNA	NULL
binding	NULL
ac-tivity	NULL
;	NULL
formation	NULL
of	NULL
slowly	NULL
migrating	NULL
complexes	NULL
;	NULL
and	NULL
weak	NULL
inducibility	NULL
of	NULL
this	NULL
DNA	NULL
binding	NULL
activity	NULL
by	NULL
either	NULL
PMA	NULL
or	NULL
TNF	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
A	NULL
,	NULL
lanes	NULL
4-6	NULL
and	NULL
10-12	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
profile	NULL
was	NULL
observed	NULL
using	NULL
the	NULL
HIV	NULL
enhancer	NULL
sequence	NULL
as	NULL
probe	NULL
although	NULL
about	NULL
fivefold	NULL
less	NULL
complex	NULL
A	NULL
was	NULL
detected	NULL
with	NULL
this	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
)	NULL
.	NULL

In	NULL
competition	NULL
experiments	NULL
,	NULL
both	NULL
the	NULL
P2	NULL
oligonucleotide	NULL
and	NULL
the	NULL
HIV	NULL
enhancer	NULL
oligonucleotide	NULL
were	NULL
able	NULL
to	NULL
compete	NULL
effectively	NULL
for	NULL
the	NULL
TNF-induced	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activities	NULL
in	NULL
PLB-985	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
A	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
PLB-IIHB	NULL
cells	NULL
only	NULL
the	NULL
P2	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
,	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
8	NULL
)	NULL
competed	NULL
efficiently	NULL
for	NULL
the	NULL
slower	NULL
migrating	NULL
constitutive	NULL
A	NULL
complex	NULL
.	NULL

The	NULL
HIV	NULL
enhancer	NULL
competed	NULL
weakly	NULL
for	NULL
this	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
,	NULL
and	NULL
9	NULL
)	NULL
.	NULL

In	NULL
dis	NULL
755	NULL
Roulston	NULL
et	NULL
al	NULL
.	NULL

sociation	NULL
rate	NULL
analysis	NULL
,	NULL
complex	NULL
A	NULL
dissociated	NULL
from	NULL
the	NULL
radiolabeled	NULL
probe	NULL
with	NULL
a	NULL
T	NULL
;	NULL
,	NULL
of	NULL
<	NULL
4	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
excess	NULL
P2	NULL
oligonucleotide	NULL
,	NULL
whereas	NULL
addition	NULL
of	NULL
excess	NULL
HIV	NULL
enhancer	NULL
failed	NULL
to	NULL
dissociate	NULL
the	NULL
A	NULL
complex	NULL
(	NULL
Ty	NULL
>	NULL
30	NULL
min	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
proteins	NULL
involved	NULL
complex	NULL
A	NULL
bound	NULL
preferentially	NULL
to	NULL
the	NULL
5-GGGAAATTCC-3	NULL
'	NULL
site	NULL
.	NULL

These	NULL
proteins	NULL
had	NULL
a	NULL
>	NULL
20-fold	NULL
higher	NULL
affinity	NULL
for	NULL
P2	NULL
sequences	NULL
than	NULL
for	NULL
HIV	NULL
enhancer	NULL
sequences	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
sequence	NULL
specificity	NULL
of	NULL
complex	NULL
A	NULL
binding	NULL
,	NULL
mutational	NULL
analysis	NULL
of	NULL
the	NULL
NF-KB	NULL
sites	NULL
was	NULL
performed	NULL
.	NULL

Mutations	NULL
that	NULL
altered	NULL
the	NULL
5°	NULL
guanine	NULL
residues	NULL
of	NULL
the	NULL
HIV	NULL
or	NULL
P2	NULL
oligonucleotides	NULL
completely	NULL
inhibited	NULL
NF-	NULL
«	NULL
B	NULL
competition	NULL
in	NULL
PLB-985	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
A	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
,	NULL
whereas	NULL
mutation	NULL
of	NULL
the	NULL
AA	NULL
dinucleotide	NULL
to	NULL
CG	NULL
partially	NULL
inhibited	NULL
>	NULL
60	NULL
%	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
A	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

With	NULL
extracts	NULL
from	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
only	NULL
the	NULL
homologous	NULL
P2	NULL
oligonucleotide	NULL
competed	NULL
effectively	NULL
for	NULL
complex	NULL
A	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
A	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
either	NULL
the	NULL
5°	NULL
guanine	NULL
residues	NULL
or	NULL
the	NULL
AA	NULL
dinucleotide	NULL
of	NULL
the	NULL
NF-KB	NULL
site	NULL
blocked	NULL
competition	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
A	NULL
,	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
complex	NULL
A	NULL
is	NULL
composed	NULL
of	NULL
NF-KB	NULL
related	NULL
proteins	NULL
that	NULL
require	NULL
the	NULL
entire	NULL
P2	NULL
site	NULL
for	NULL
efficient	NULL
DNA	NULL
binding	NULL
.	NULL

The	NULL
proteins	NULL
involved	NULL
in	NULL
protein-DNA	NULL
complex	NULL
formation	NULL
were	NULL
evaluated	NULL
by	NULL
in	NULL
situ	NULL
UV	NULL
crosslinking	NULL
analysis	NULL
using	NULL
BUdR-substituted	NULL
P2	NULL
and	NULL
HIV	NULL
enhancer	NULL
probes	NULL
together	NULL
with	NULL
extracts	NULL
from	NULL
the	NULL
TNF-treated	NULL
PLB-985	NULL
or	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

The	NULL
regions	NULL
of	NULL
the	NULL
mobility	NULL
shift	NULL
assay	NULL
corresponding	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
complex	NULL
A	NULL
were	NULL
cut	NULL
from	NULL
the	NULL
gel	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
A	NULL
)	NULL
,	NULL
crosslinked	NULL
in	NULL
situ	NULL
for	NULL
30	NULL
min	NULL
and	NULL
resolved	NULL
on	NULL
an	NULL
SDS	NULL
polyacrylamide	NULL
gel	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
B	NULL
)	NULL
.	NULL

Both	NULL
P2	NULL
and	NULL
HIV	NULL
probes	NULL
bound	NULL
proteins	NULL
of	NULL
50	NULL
,	NULL
40	NULL
,	NULL
and	NULL
20	NULL
kD	NULL
from	NULL
PLB-985	NULL
cell	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
B	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
proteins	NULL
of	NULL
75	NULL
and	NULL
60	NULL
kD	NULL
interacted	NULL
weakly	NULL
with	NULL
the	NULL
HIV	NULL
enhancer	NULL
.	NULL

Differences	NULL
in	NULL
protein	NULL
migration	NULL
were	NULL
attributable	NULL
to	NULL
the	NULL
size	NULL
difference	NULL
between	NULL
the	NULL
two	NULL
probes	NULL
.	NULL

It	NULL
is	NULL
striking	NULL
that	NULL
the	NULL
HIV	NULL
probe	NULL
did	NULL
not	NULL
efficiently	NULL
bind	NULL
proteins	NULL
from	NULL
the	NULL
PLB-IIIB	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
whereas	NULL
multiple	NULL
proteins	NULL
ranging	NULL
in	NULL
size	NULL
from	NULL
50-105	NULL
kD	NULL
were	NULL
detected	NULL
using	NULL
the	NULL
P2	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Three	NULL
prominent	NULL
proteins	NULL
of	NULL
100	NULL
,	NULL
90	NULL
,	NULL
and	NULL
70	NULL
kD	NULL
were	NULL
identified	NULL
,	NULL
as	NULL
well	NULL
as	NULL
several	NULL
other	NULL
proteins	NULL
.	NULL

Comparison	NULL
of	NULL
uninduced	NULL
and	NULL
TNF	NULL
induced	NULL
extracts	NULL
by	NULL
UV	NULL
crosslinking	NULL
also	NULL
demonstrated	NULL
that	NULL
only	NULL
the	NULL
70-kD	NULL
protein	NULL
was	NULL
inducible	NULL
by	NULL
TNF	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Overall	NULL
,	NULL
the	NULL
profiles	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
proteins	NULL
in	NULL
PLB-985	NULL
and	NULL
PLB-IIHIB	NULL
cells	NULL
differ	NULL
dramatically	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
nature	NULL
of	NULL
NF-	NULL
«	NULL
B-like	NULL
interactions	NULL
is	NULL
altered	NULL
in	NULL
the	NULL
HIV-infected	NULL
cells	NULL
.	NULL

Transcription	NULL
of	NULL
IFN-	NULL
and	NULL
IFN-	NULL
Genes	NULL
.	NULL

To	NULL
examine	NULL
if	NULL
changes	NULL
in	NULL
the	NULL
state	NULL
of	NULL
differentiation	NULL
or	NULL
NF-	NULL
«	NULL
B-related	NULL
activities	NULL
affected	NULL
gene	NULL
expression	NULL
,	NULL
the	NULL
transcription	NULL
of	NULL
IFN-	NULL
«	NULL
and	NULL
IFN-	NULL
(	NULL
genes	NULL
was	NULL
investigated	NULL
in	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

In	NULL
PLB-985	NULL
cells	NULL
,	NULL
IFN-	NULL
RNA	NULL
was	NULL
induced	NULL
by	NULL
Sendai	NULL
virus	NULL
infection	NULL
6	NULL
h	NULL
after	NULL
infection	NULL
.	NULL

In	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
a	NULL
low	NULL
level	NULL
of	NULL
constitutive	NULL
IFN-G	NULL
mRNA	NULL
was	NULL
detected	NULL
and	NULL
coinfection	NULL
by	NULL
Sendai	NULL
virus	NULL
resulted	NULL
in	NULL
three-	NULL
to	NULL
fourfold	NULL
more	NULL
IFN-	NULL
@	NULL
RNA	NULL
than	NULL
similarly	NULL
induced	NULL
PLB-985	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
these	NULL
results	NULL
,	NULL
IFN-ax	NULL
transcription	NULL
was	NULL
only	NULL
weakly	NULL
induced	NULL
in	NULL
PLB-985	NULL
cells	NULL
,	NULL
but	NULL
50-fold	NULL
higher	NULL
levels	NULL
of	NULL
IFN-RNA	NULL
were	NULL
detected	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
PLB-985	NULL
PLB-IIIB	NULL
1	NULL
_	NULL
_2	NULL
3	NULL
4	NULL
5	NULL
omy	NULL
:	NULL
%	NULL
u	NULL
»	NULL
M	NULL
c-fms	NULL
-	NULL
»	NULL
B-actin	NULL
-	NULL
»	NULL
0	NULL
-	NULL
2	NULL
6	NULL
10	NULL
24	NULL
0	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
2	NULL
6	NULL
10	NULL
24	NULL
Hours	NULL
after	NULL
PMA	NULL
Addition	NULL
Figure	NULL
4	NULL
.	NULL

-	NULL
Modulation	NULL
of	NULL
c-myc	NULL
and	NULL
c-fms	NULL
RNA	NULL
levels	NULL
in	NULL
PMA-treated	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

Total	NULL
RNA	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
from	NULL
PMA-treated	NULL
PLB-985	NULL
cells	NULL
(	NULL
lanes	NULL
1-5	NULL
)	NULL
or	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
lanes	NULL
6-10	NULL
)	NULL
was	NULL
electrophoresed	NULL
in	NULL
a	NULL
1	NULL
%	NULL
formaldehyde	NULL
gel	NULL
,	NULL
transferred	NULL
to	NULL
a	NULL
nylon	NULL
membrane	NULL
,	NULL
and	NULL
hybridized	NULL
sequentially	NULL
with	NULL
c-myc	NULL
,	NULL
c-fms	NULL
,	NULL
and	NULL
B-actin	NULL
probes	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

RNA	NULL
was	NULL
isolated	NULL
at	NULL
0	NULL
,	NULL
2	NULL
,	NULL
6	NULL
,	NULL
10	NULL
,	NULL
and	NULL
24	NULL
h	NULL
after	NULL
treatment	NULL
(	NULL
shown	NULL
below	NULL
the	NULL
autoradiogram	NULL
)	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
positions	NULL
of	NULL
the	NULL
correct	NULL
RNA	NULL
signal	NULL
.	NULL

indicate	NULL
that	NULL
HIV	NULL
infection	NULL
of	NULL
myelomonoblastic	NULL
cells	NULL
results	NULL
in	NULL
selection	NULL
of	NULL
a	NULL
cell	NULL
population	NULL
with	NULL
a	NULL
more	NULL
monocytic	NULL
phenotype	NULL
by	NULL
several	NULL
criteria	NULL
,	NULL
changes	NULL
in	NULL
NF-	NULL
«	NULL
B~like	NULL
protein-DNA	NULL
interactions	NULL
and	NULL
modulation	NULL
of	NULL
cytokine	NULL
gene	NULL
expression	NULL
.	NULL

Discussion	NULL
HIV-1	NULL
infection	NULL
of	NULL
PLB-985	NULL
blast	NULL
cells	NULL
resulted	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
a	NULL
chronically	NULL
infected	NULL
cell	NULL
population	NULL
(	NULL
PLB-IIIB	NULL
)	NULL
possessing	NULL
morphological	NULL
,	NULL
immunological	NULL
,	NULL
histochemical	NULL
,	NULL
and	NULL
molecular	NULL
characteristics	NULL
of	NULL
monocytes	NULL
.	NULL

Concomitant	NULL
with	NULL
HIV	NULL
infection	NULL
and	NULL
myeloid	NULL
differentiation	NULL
,	NULL
dramatic	NULL
alterations	NULL
in	NULL
the	NULL
protein-DNA	NULL
interactions	NULL
occurring	NULL
at	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
recognition	NULL
sequence	NULL
5-GGGAAATTCC-3	NULL
'	NULL
were	NULL
ob-served	NULL
.	NULL

Distinct	NULL
proteins	NULL
of	NULL
100	NULL
,	NULL
90	NULL
,	NULL
and	NULL
70	NULL
kD	NULL
were	NULL
identified	NULL
in	NULL
PLB-IHIB	NULL
cells	NULL
that	NULL
possessed	NULL
a	NULL
higher	NULL
affinity	NULL
for	NULL
the	NULL
more	NULL
symmetric	NULL
PRDII	NULL
binding	NULL
site	NULL
than	NULL
for	NULL
the	NULL
HIV	NULL
enhancer	NULL
sites	NULL
.	NULL

These	NULL
two	NULL
sequences	NULL
differ	NULL
only	NULL
by	NULL
the	NULL
-AA-	NULL
and	NULL
-CT	NULL
dinucleotides	NULL
in	NULL
the	NULL
middle	NULL
of	NULL
the	NULL
binding	NULL
site	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
more	NULL
palindromic	NULL
recognition	NULL
sequence	NULL
.	NULL

NF-KB	NULL
represents	NULL
a	NULL
family	NULL
of	NULL
rel-related	NULL
DNA	NULL
binding	NULL
poly-peptides	NULL
that	NULL
include	NULL
p45	NULL
,	NULL
p50	NULL
,	NULL
p55	NULL
,	NULL
p65	NULL
,	NULL
p75	NULL
,	NULL
and	NULL
p85	NULL
(	NULL
c-rel	NULL
)	NULL
.	NULL

The	NULL
activities	NULL
of	NULL
these	NULL
proteins	NULL
are	NULL
controlled	NULL
at	NULL
several	NULL
regulatory	NULL
levels	NULL
.	NULL

Multiple	NULL
DNA	NULL
binding	NULL
NF-KB	NULL
heterodi-mers	NULL
with	NULL
distinct	NULL
affinities	NULL
for	NULL
DNA	NULL
can	NULL
form	NULL
in	NULL
vitro	NULL
(	NULL
22	NULL
,	NULL
42	NULL
,	NULL
L.	NULL
Cohen	NULL
and	NULL
J.	NULL
Hiscott	NULL
,	NULL
manuscript	NULL
submitted	NULL
for	NULL
pub-lication	NULL
}	NULL
,	NULL
single	NULL
base	NULL
changes	NULL
in	NULL
the	NULL
NF-KB	NULL
site	NULL
can	NULL
significantly	NULL
alter	NULL
the	NULL
binding	NULL
affinity	NULL
of	NULL
these	NULL
heterodimers	NULL
.	NULL

Biphasic	NULL
kinetics	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
has	NULL
been	NULL
described	NULL
,	NULL
characterized	NULL
by	NULL
rapid	NULL
appearance	NULL
of	NULL
p55	NULL
and	NULL
p75	NULL
forms	NULL
of	NULL
NF-KB	NULL
within	NULL
756	NULL
NF-kB	NULL
Activity	NULL
in	NULL
HIV-1-infected	NULL
Monocytic	NULL
Cells	NULL
'xa	NULL
[	NULL
duwoo	NULL
aures	NULL
ay	NULL
:	NULL
yam	NULL
aqgord	NULL
se	NULL
pasn	NULL
sem	NULL
spuoapnuo®go	NULL
ssoueguo	NULL
Ajp	NULL
au1	NULL
,	NULL
(	NULL
g	NULL
)	NULL
'194981q	NULL
oy	NULL
?	NULL

4q	NULL
poseotput	NULL
;	NULL
st	NULL
gx-gpj	NULL
{	NULL
smoire	NULL
4q	NULL
poreotput	NULL
are	NULL
xo	NULL
[	NULL
dioo	NULL
(	NULL
su	NULL
)	NULL
agmodsuou	NULL
e	NULL
pue	NULL
y	NULL
xardwo	NULL
;	NULL
(	NULL
z	NULL
;	NULL
pue	NULL
§	NULL
sous	NULL
]	NULL
4	NULL
9J	NULL
Jof	NULL
quaunesan	NULL
-IN	NULL
,	NULL
J	NULL
Jo	NULL
'	NULL
(	NULL
Jf	NULL
pue	NULL
g	NULL
saue	NULL
;	NULL
)	NULL
q	NULL
p	NULL
10	NULL
}	NULL
qusunron	NULL
oN	NULL
'	NULL
(	NULL
g	NULL
pue	NULL
¢	NULL
soue	NULL
;	NULL
)	NULL
q	NULL
9f	NULL
sof	NULL
qusunron	NULL
yprq	NULL
``	NULL
(	NULL
¢	NULL
pus	NULL
z	NULL
souey	NULL
)	NULL
q	NULL
p	NULL
sof	NULL
queuntan	NULL
yp	NULL
Joye	NULL
'	NULL
(	NULL
q	NULL
;	NULL
pues	NULL
'	NULL
'	NULL
p	NULL
'	NULL
J	NULL
szoonput	NULL
Yim	NULL
juaunean	NULL
noyjim	NULL
wor	NULL
;	NULL
paredord	NULL
arom	NULL
syoerixq	NULL
'spoyjopy	NULL
pur	NULL
steusrepy	NULL
ut	NULL
paqimsap	NULL
se	NULL
appospnuofffo	NULL
z4	NULL
243	NULL
Sutsn	NULL
surs	NULL
;	NULL
ord	NULL
101	NULL
paz	NULL
{	NULL
feus	NULL
aram	NULL
(	NULL
z7-qf	NULL
pus	NULL
9-p	NULL
sour	NULL
}	NULL
)	NULL
@	NULL
III-8	NULL
Td	NULL
pus	NULL
(	NULL
6-4	NULL
pue	NULL
'	NULL
g-7	NULL
sourt	NULL
)	NULL
ege-g'Tq	NULL
wos	NULL
(	NULL
37	NULL
)	NULL
of	NULL
)	NULL
soemme	NULL
oo	NULL
sou	NULL
A	NULL
(	NULL
y	NULL
)	NULL
stjco	NULL
7d	NULL
P4®	NULL
586-8	NULL
Id	NULL
PoI®4	NULL
AN.L	NULL
pus	NULL
yWwq	NULL
ut	NULL
sumsord	NULL
Surpurgq-gy-4p	NULL
Jo	NULL
sis	NULL
{	NULL
feue	NULL
wrys	NULL
Anpgop	NULL
|	NULL
*g	NULL
ani	NULL
glll-87d4	NULL
_	NULL
$	NULL
86-871d	NULL
glII-871d4d	NULL
_	NULL
§	NULL
$	NULL
86-871d	NULL
gllI-g87d	NULL
_	NULL
S86-871d	NULL
gllI-g87d4d	NULL
_	NULL
§	NULL
$	NULL
86-81d	NULL
«	NULL
p	NULL
wo	NULL
w	NULL
SU-	NULL
»	NULL
>	NULL
m	NULL
a	NULL
We	NULL
@	NULL
»	NULL
.	NULL
'	NULL

mgﬁ	NULL
.	NULL

mi	NULL
”	NULL
.	NULL

y	NULL
--	NULL
~*	NULL
M	NULL
Y	NULL
-m	NULL
ZL	NULL
ll	NULL
Ol	NULL
608g	NULL
L200	NULL
9	NULL
§	NULL
p	NULL
g	NULL
2	NULL
Lo	NULL
21	NULL
IL	NULL
OL	NULL
6	NULL
8	NULL
2	NULL
9	NULL
g	NULL
#	NULL
8	NULL
2	NULL
G	NULL
waw	NULL
;	NULL
ea11	NULL
4NL	NULL
waw	NULL
}	NULL
2e311	NULL
YW	NULL
JNJ	NULL
wwaw	NULL
}	NULL
231	NULL
]	NULL
YVwWd	NULL
aqgold	NULL
AIH	NULL
-	NULL
g	NULL
aqoid	NULL
2d	NULL
-	NULL
V	NULL
A	NULL
PLB-985	NULL
uninduced	NULL
TNFa	NULL
(	NULL
5h	NULL
)	NULL
TNFa	NULL
(	NULL
16h	NULL
)	NULL
--	NULL
P2	NULL
HIV	NULL
P2	NULL
HIV	NULL
P2	NULL
HIV	NULL
xB	NULL
-	NULL
<	NULL
4-ns	NULL
1	NULL
_	NULL
2	NULL
3	NULL
4	NULL
0	NULL
50	NULL
6	NULL
7	NULL
8	NULL
B	NULL
PLB-IB	NULL
uninduced	NULL
TNFa	NULL
(	NULL
5h	NULL
)	NULL
TNFa	NULL
(	NULL
16h	NULL
)	NULL
--	NULL
P2	NULL
HIV	NULL
P2	NULL
HIV	NULL
--	NULL
P2	NULL
HIV	NULL
“	NULL
ﬂu-	NULL
“	NULL
u	NULL
“	NULL
minutes	NULL
,	NULL
and	NULL
by	NULL
the	NULL
delayed	NULL
induction	NULL
of	NULL
p50	NULL
and	NULL
p85	NULL
after	NULL
several	NULL
hours	NULL
of	NULL
PMA	NULL
treatment	NULL
(	NULL
32	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
indicate	NULL
that	NULL
variations	NULL
in	NULL
DNA	NULL
affinity	NULL
,	NULL
heterodimer	NULL
forma-tion	NULL
,	NULL
and	NULL
induction	NULL
kinetics	NULL
may	NULL
contribute	NULL
to	NULL
both	NULL
positive	NULL
and	NULL
negative	NULL
transcriptional	NULL
control	NULL
.	NULL

With	NULL
the	NULL
availability	NULL
of	NULL
cloned	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
,	NULL
it	NULL
is	NULL
now	NULL
clear	NULL
that	NULL
transcription	NULL
of	NULL
NF-	NULL
«	NULL
B-related	NULL
genes	NULL
represents	NULL
an	NULL
Figure	NULL
6	NULL
,	NULL
(	NULL
A	NULL
)	NULL
Competition	NULL
of	NULL
NF-	NULL
«	NULL
B-binding	NULL
proteins	NULL
in	NULL
PLB-985	NULL
cells	NULL
.	NULL

The	NULL
protein-DNA	NULL
complexes	NULL
present	NULL
in	NULL
uninduced	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
5h	NULL
TNF-treated	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
or	NULL
16-h	NULL
TNF-treated	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
extracts	NULL
were	NULL
competed	NULL
using	NULL
a	NULL
125-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
P2	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
8	NULL
)	NULL
or	NULL
unlabeled	NULL
HIV	NULL
enhancer	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
,	NULL
and	NULL
9	NULL
)	NULL
.	NULL

The	NULL
bracket	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
NF-KB	NULL
complexes	NULL
;	NULL
and	NULL
the	NULL
arrow	NULL
indicates	NULL
the	NULL
nonspecific	NULL
(	NULL
ns	NULL
)	NULL
complex	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Competition	NULL
NF-	NULL
«	NULL
B-binding	NULL
proteins	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

The	NULL
protein-DNA	NULL
complexes	NULL
present	NULL
in	NULL
uninduced	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
5-h	NULL
TNF-treated	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
or	NULL
16-h	NULL
TNF-treated	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
extracts	NULL
were	NULL
competed	NULL
using	NULL
a	NULL
125-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
P2	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
8	NULL
)	NULL
or	NULL
unlabeled	NULL
HIV	NULL
enhancer	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
,	NULL
and	NULL
9	NULL
)	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
position	NULL
of	NULL
the	NULL
slowly	NULL
migrating	NULL
A	NULL
complex	NULL
and	NULL
the	NULL
nonspecific	NULL
complex	NULL
.	NULL

«	NULL
ns	NULL
other	NULL
important	NULL
level	NULL
of	NULL
regulation	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
p50	NULL
,	NULL
IxB	NULL
,	NULL
and	NULL
c-rel	NULL
gene	NULL
transcription	NULL
is	NULL
rapidly	NULL
induced	NULL
by	NULL
phorbol	NULL
esters	NULL
and	NULL
mitogens	NULL
(	NULL
29	NULL
,	NULL
43-45	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
a	NULL
new	NULL
NF-	NULL
«	NULL
B	NULL
100-kD	NULL
precursor	NULL
gene	NULL
was	NULL
described	NULL
recently	NULL
that	NULL
is	NULL
regulated	NULL
by	NULL
both	NULL
alternate	NULL
splicing	NULL
and	NULL
proteolytic	NULL
cleavage	NULL
to	NULL
yield	NULL
two	NULL
forms	NULL
of	NULL
a	NULL
distinct	NULL
p50	NULL
subunit	NULL
(	NULL
52	NULL
)	NULL
.	NULL

HIV-1	NULL
infection	NULL
may	NULL
have	NULL
an	NULL
impact	NULL
on	NULL
posttranslational	NULL
processing	NULL
of	NULL
NF-KB	NULL
758	NULL
NF-	NULL
«	NULL
B	NULL
Activity	NULL
in	NULL
HIV-1-infected	NULL
Monocytic	NULL
Cells	NULL
.01	NULL
0	NULL
10	NULL
20	NULL
30	NULL
Tiz=2	NULL
min	NULL
Time	NULL
(	NULL
min	NULL
)	NULL
Figure	NULL
7	NULL
.	NULL

_	NULL
Dissociation	NULL
rate	NULL
analysis	NULL
of	NULL
the	NULL
P2	NULL
complex	NULL
.	NULL

The	NULL
P2	NULL
probe	NULL
(	NULL
0.2	NULL
ng	NULL
)	NULL
was	NULL
mixed	NULL
with	NULL
protein	NULL
from	NULL
TNF-induced	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
5	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dl	NULL
:	NULL
dC	NULL
)	NULL
as	NULL
nonspecific	NULL
competitor	NULL
;	NULL
at	NULL
To	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
complex	NULL
A	NULL
was	NULL
determined	NULL
.	NULL

A	NULL
125-fold	NULL
molar	NULL
excess	NULL
of	NULL
P2	NULL
oligonucleotide	NULL
or	NULL
HIV	NULL
enhancer	NULL
oligonucleotide	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
,	NULL
and	NULL
at	NULL
2-min	NULL
intervals	NULL
the	NULL
amount	NULL
of	NULL
complex	NULL
A	NULL
remaining	NULL
was	NULL
measured	NULL
.	NULL

The	NULL
relative	NULL
intensity	NULL
of	NULL
the	NULL
bands	NULL
at	NULL
different	NULL
times	NULL
was	NULL
quantified	NULL
by	NULL
laser	NULL
densitometry	NULL
and	NULL
plotted	NULL
as	NULL
a	NULL
function	NULL
of	NULL
the	NULL
amount	NULL
of	NULL
complex	NULL
at	NULL
To	NULL
.	NULL

(	NULL
@	NULL
)	NULL
P2	NULL
;	NULL
(	NULL
0	NULL
)	NULL
HIV	NULL
.	NULL

A	NULL
102	NULL
3	NULL
40	NULL
50	NULL
6	NULL
7	NULL
8	NULL
since	NULL
the	NULL
p105	NULL
precursor	NULL
may	NULL
be	NULL
cleaved	NULL
by	NULL
the	NULL
HIV-1	NULL
protease	NULL
in	NULL
vitro	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Several	NULL
possibilities	NULL
may	NULL
account	NULL
for	NULL
the	NULL
dramatic	NULL
differences	NULL
in	NULL
DNA	NULL
binding	NULL
activity	NULL
between	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
distinct	NULL
or	NULL
NF-	NULL
«	NULL
B-related	NULL
proteins	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
may	NULL
occur	NULL
as	NULL
a	NULL
result	NULL
of	NULL
monocytic	NULL
differentiation	NULL
.	NULL

Recent	NULL
studies	NULL
indicate	NULL
that	NULL
c-re/	NULL
may	NULL
be	NULL
tran-scriptionally	NULL
induced	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Altered	NULL
stoichiometry	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
because	NULL
of	NULL
changes	NULL
in	NULL
precursor	NULL
processing	NULL
may	NULL
result	NULL
in	NULL
binding	NULL
of	NULL
larger	NULL
,	NULL
incompletely	NULL
processed	NULL
subunits	NULL
.	NULL

The	NULL
100-	NULL
and	NULL
105-kD	NULL
p50	NULL
precursors	NULL
may	NULL
not	NULL
be	NULL
processed	NULL
efficiently	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
new	NULL
combinations	NULL
of	NULL
DNA-binding	NULL
heterodimers	NULL
,	NULL
possibly	NULL
via	NULL
interactions	NULL
of	NULL
the	NULL
ankyrin	NULL
repeat	NULL
.	NULL

Overexpression	NULL
of	NULL
chromatin-associated	NULL
proteins	NULL
may	NULL
stabilize	NULL
the	NULL
binding	NULL
of	NULL
proteins	NULL
that	NULL
would	NULL
otherwise	NULL
possess	NULL
an	NULL
affinity	NULL
too	NULL
low	NULL
to	NULL
be	NULL
detected	NULL
by	NULL
mobility	NULL
shift	NULL
analysis	NULL
.	NULL

Recently	NULL
a	NULL
protein	NULL
capable	NULL
of	NULL
interacting	NULL
with	NULL
the	NULL
PRDII	NULL
site	NULL
but	NULL
not	NULL
other	NULL
NF-KB	NULL
sites	NULL
has	NULL
been	NULL
described	NULL
that	NULL
may	NULL
act	NULL
as	NULL
such	NULL
an	NULL
accessory	NULL
protein	NULL
and	NULL
,	NULL
in	NULL
part	NULL
,	NULL
explain	NULL
the	NULL
unique	NULL
pattern	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
observed	NULL
only	NULL
in	NULL
the	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
47	NULL
)	NULL
.	NULL

The	NULL
HMG	NULL
I/Y	NULL
proteins	NULL
are	NULL
chromatin-associated	NULL
proteins	NULL
that	NULL
bind	NULL
in	NULL
the	NULL
minor	NULL
groove	NULL
of	NULL
DNA	NULL
to	NULL
sequences	NULL
that	NULL
are	NULL
A'T	NULL
rich	NULL
or	NULL
that	NULL
possess	NULL
Oct-1	NULL
like	NULL
recognition	NULL
sites	NULL
10	NULL
11	NULL
12	NULL
'	NULL
'	NULL
``	NULL
'	NULL
Uww	NULL
W	NULL
``	NULL
7	NULL
,	NULL
tJ	NULL
,	NULL
A	NULL
&	NULL
&	NULL
“	NULL
o	NULL
,	NULL
02°	NULL
!	NULL

do	NULL
)	NULL
”	NULL
6	NULL
Competitor	NULL
PLB-985	NULL
Competitor	NULL
HIV	NULL
P2	NULL
HIV	NULL
mut	NULL
P2	NULL
mut	NULL
A	NULL
P2	NULL
mut	NULL
B	NULL
n	NULL
e	NULL
0	NULL
20	NULL
40	NULL
60	NULL
80	NULL
100	NULL
120	NULL
DNA	NULL
Binding	NULL
activity	NULL
(	NULL
%	NULL
)	NULL
Oligonucleotide	NULL
Sequences	NULL
«	NULL
<	NULL
-	NULL
ns	NULL
``	NULL
/	NULL
``	NULL
m	NULL
*	NULL
,	NULL
%	NULL
G	NULL
,	NULL
Ob	NULL
,	NULL
Figure	NULL
8	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
4	NULL
*	NULL
&	NULL
NF-	NULL
«	NULL
B-binding	NULL
sites	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
protein-DNA	NULL
complexes	NULL
present	NULL
in	NULL
PLB-985	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
were	NULL
competed	NULL
using	NULL
a	NULL
125-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
HIV	NULL
enhancer	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
8	NULL
)	NULL
,	NULL
the	NULL
HIV	NULL
mutated	NULL
enhancer	NULL
{	NULL
lanes	NULL
3	NULL
and	NULL
9	NULL
)	NULL
,	NULL
the	NULL
P2	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
10	NULL
)	NULL
,	NULL
the	NULL
P2	NULL
mutant	NULL
A	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
11	NULL
)	NULL
,	NULL
and	NULL
the	NULL
P2	NULL
mutant	NULL
B	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
12	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
these	NULL
oligonucleotides	NULL
is	NULL
shown	NULL
adjacent	NULL
to	NULL
the	NULL
quantification	NULL
data	NULL
.	NULL

Altered	NULL
nucleotides	NULL
relative	NULL
to	NULL
the	NULL
sequence	NULL
of	NULL
wild-type	NULL
P2	NULL
are	NULL
indicated	NULL
by	NULL
small	NULL
letters	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quantification	NULL
of	NULL
mutant	NULL
competition	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
remaining	NULL
after	NULL
competition	NULL
was	NULL
measured	NULL
by	NULL
laser	NULL
densitometry	NULL
and	NULL
quantified	NULL
relative	NULL
to	NULL
the	NULL
amount	NULL
of	NULL
binding	NULL
obtained	NULL
without	NULL
competitor	NULL
.	NULL

The	NULL
results	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
duplicate	NULL
competition	NULL
experiments	NULL
.	NULL

(	NULL
2	NULL
)	NULL
amount	NULL
of	NULL
complex	NULL
remaining	NULL
from	NULL
PLB-985	NULL
extracts	NULL
;	NULL
(	NULL
MB	NULL
)	NULL
amount	NULL
of	NULL
complex	NULL
remaining	NULL
from	NULL
PLB-IIIB	NULL
extracts	NULL
.	NULL

&	NULL
PLB-IIIB	NULL
G	NULL
GGA	NULL
ct	NULL
TTCC	NULL
G	NULL
G	NULL
GAA	NULL
aATTCC	NULL
c	NULL
a	NULL
t	NULL
g	NULL
g	NULL
tTTCC	NULL
a	NULL
c	NULL
t	NULL
AAATTCC	NULL
G	NULL
GGA	NULL
c	NULL
gTTCC	NULL
G	NULL
G	NULL
GRNN	NULL
Y	NULL
Y	NULL
CC	NULL
Consensus	NULL
Sequence	NULL
!	NULL

RB	NULL
_	NULL
a-	NULL
ns	NULL
Probe	NULL
P2	NULL
HIV	NULL
P2	NULL
HIV	NULL
PLB-985	NULL
PLB-IIIB	NULL
B	NULL
M	NULL
1	NULL
2	NULL
M	NULL
3	NULL
116	NULL
-	NULL
116	NULL
97	NULL
-	NULL
97	NULL
-	NULL
N	NULL
-	NULL
<	NULL
#	NULL
--	NULL
75	NULL
#	NULL
66	NULL
-	NULL
-a-	NULL
60	NULL
66	NULL
l	NULL
50	NULL
l	NULL
40	NULL
45	NULL
-	NULL
45	NULL
to	NULL
#	NULL
L	NULL
«	NULL
<	NULL
--	NULL
-	NULL
20	NULL
29	NULL
29	NULL
i	NULL
``	NULL
.	NULL

A	NULL
-	NULL
<	NULL
ea	NULL
--	NULL
105	NULL
-a-	NULL
100	NULL
-	NULL
«	NULL
a	NULL
--	NULL
90	NULL
--	NULL
-	NULL
85	NULL
70	NULL
-a-	NULL
60	NULL
--	NULL
-	NULL
50	NULL
Figure	NULL
9	NULL
.	NULL

-	NULL
UV	NULL
crosslinking	NULL
analysis	NULL
of	NULL
proteins	NULL
binding	NULL
to	NULL
HIV	NULL
and	NULL
P2	NULL
oligonucleotides	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Mobility	NULL
shift	NULL
analysis	NULL
of	NULL
NF-KB	NULL
binding	NULL
activities	NULL
in	NULL
PLB-985	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
and	NULL
PLB-IIIB	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
after	NULL
treatment	NULL
with	NULL
TNF	NULL
for	NULL
5	NULL
h	NULL
using	NULL
BUdR	NULL
substituted	NULL
,	NULL
**P-labeled	NULL
P2	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
or	NULL
HIV	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
probes	NULL
.	NULL

'The	NULL
nonspecific	NULL
complex	NULL
(	NULL
ns	NULL
)	NULL
was	NULL
not	NULL
analyzed	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
region	NULL
of	NULL
the	NULL
gel	NULL
containing	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
A	NULL
was	NULL
cut	NULL
from	NULL
the	NULL
native	NULL
gel	NULL
,	NULL
exposed	NULL
to	NULL
UV	NULL
(	NULL
302	NULL
nm	NULL
)	NULL
for	NULL
30	NULL
min	NULL
,	NULL
soaked	NULL
in	NULL
SDS	NULL
sample	NULL
buffer	NULL
,	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
10	NULL
%	NULL
SDS	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
molecular	NULL
_P2	NULL
HIV	NULL
P2	NULL
HIV	NULL
mass	NULL
standards	NULL
(	NULL
M	NULL
)	NULL
are	NULL
indicated	NULL
;	NULL
the	NULL
nllolec-PLB-985	NULL
PLB-11IB	NULL
ules	NULL
mass	NULL
of	NULL
crondinked	NULL
proteins	NULL
are	NULL
indicted	NULL
~	NULL
~	NULL
with	NULL
arrows	NULL
.	NULL

(	NULL
48	NULL
,	NULL
49	NULL
)	NULL
.	NULL

Increased	NULL
HMG	NULL
I/Y	NULL
protein	NULL
levels	NULL
have	NULL
been	NULL
detected	NULL
in	NULL
undifferentiated	NULL
,	NULL
rapidly	NULL
growing	NULL
and	NULL
transformed	NULL
cells	NULL
(	NULL
50	NULL
,	NULL
51	NULL
)	NULL
.	NULL

HIV-1	NULL
infection	NULL
may	NULL
be	NULL
sufficient	NULL
to	NULL
increase	NULL
HMG	NULL
I/Y	NULL
levels	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

In	NULL
parental	NULL
PLB-985	NULL
cells	NULL
,	NULL
PMA	NULL
treatment	NULL
resulted	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
NF-KB	NULL
binding	NULL
activity	NULL
and	NULL
monocytic	NULL
differentiation	NULL
.	NULL

These	NULL
results	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
studies	NULL
that	NULL
showed	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
,	NULL
expression	NULL
of	NULL
an	NULL
HIV-LTR	NULL
reporter	NULL
gene	NULL
,	NULL
and	NULL
monocytic	NULL
differentiation	NULL
were	NULL
coordinately	NULL
inducible	NULL
in	NULL
immature	NULL
myeloid	NULL
cells	NULL
(	NULL
HL-60	NULL
and	NULL
U937	NULL
)	NULL
.	NULL

In	NULL
the	NULL
more	NULL
mature	NULL
P388	NULL
,	NULL
THP-1	NULL
,	NULL
and	NULL
P45-1.8	NULL
cells	NULL
,	NULL
and	NULL
in	NULL
primary	NULL
macrophages	NULL
,	NULL
binding	NULL
activity	NULL
and	NULL
basal	NULL
level	NULL
expression	NULL
of	NULL
the	NULL
HIV-LTR	NULL
reporter	NULL
gene	NULL
were	NULL
constitutive	NULL
and	NULL
not	NULL
further	NULL
inducible	NULL
,	NULL
suggesting	NULL
that	NULL
NF-KB	NULL
binding	NULL
activity	NULL
is	NULL
induced	NULL
during	NULL
the	NULL
promyelocytic	NULL
to	NULL
monocytic	NULL
transition	NULL
(	NULL
39	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
other	NULL
studies	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
760	NULL
NF-	NULL
«	NULL
B	NULL
Activity	NULL
in	NULL
HIV-1-infected	NULL
Monocytic	NULL
Cells	NULL
3000	NULL
30000	NULL
IFN	NULL
2000	NULL
.	NULL

20000	NULL
.	NULL

1000	NULL
.	NULL

10000	NULL
.	NULL

Relative	NULL
RNA	NULL
Levels	NULL
)	NULL
romo	NULL
PLB-985	NULL
PLB-985	NULL
PLB-IIB	NULL
PLB-11B	NULL
Cells	NULL
Figure	NULL
10	NULL
.	NULL

Transcription	NULL
of	NULL
IFN	NULL
«	NULL
/	NULL
(	NULL
genes	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
after	NULL
Sendai	NULL
virus	NULL
induction	NULL
for	NULL
6	NULL
h.	NULL
Reverse	NULL
transcription	NULL
and	NULL
PCR-mediated	NULL
amplification	NULL
was	NULL
carried	NULL
out	NULL
using	NULL
1	NULL
ug	NULL
of	NULL
RNA	NULL
and	NULL
P-labeled	NULL
IFN-	NULL
and	NULL
IFN-	NULL
consensus	NULL
primers	NULL
(	NULL
12	NULL
)	NULL
.	NULL

The	NULL
products	NULL
of	NULL
amplification	NULL
were	NULL
resolved	NULL
by	NULL
denaturating	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

The	NULL
relative	NULL
RNA	NULL
levels	NULL
were	NULL
quantified	NULL
by	NULL
laser	NULL
densitometry	NULL
of	NULL
autoradiographs	NULL
and	NULL
presented	NULL
as	NULL
a	NULL
bar	NULL
graph	NULL
.	NULL

activity	NULL
was	NULL
not	NULL
induced	NULL
by	NULL
HIV	NULL
infection	NULL
of	NULL
U937	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
that	NULL
these	NULL
experiments	NULL
identified	NULL
but	NULL
did	NULL
not	NULL
further	NULL
characterize	NULL
a	NULL
virus	NULL
induced	NULL
,	NULL
slowly	NULL
migrating	NULL
protein-DNA	NULL
complex	NULL
associated	NULL
with	NULL
the	NULL
HIV	NULL
enhancer	NULL
(	NULL
40	NULL
)	NULL
.	NULL

In	NULL
primary	NULL
monocytes	NULL
,	NULL
both	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
slowly	NULL
migrating	NULL
complexes	NULL
were	NULL
induced	NULL
in	NULL
response	NULL
to	NULL
HIV	NULL
infection	NULL
(	NULL
40	NULL
)	NULL
.	NULL

The	NULL
PLB	NULL
cell	NULL
line	NULL
represents	NULL
a	NULL
relevant	NULL
new	NULL
myeloid	NULL
model	NULL
to	NULL
investigate	NULL
the	NULL
relationship	NULL
between	NULL
HIV	NULL
infection	NULL
,	NULL
monocytic	NULL
differentiation	NULL
,	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
these	NULL
novel	NULL
NF-KB	NULL
related	NULL
activities	NULL
.	NULL

It	NULL
will	NULL
nonetheless	NULL
be	NULL
important	NULL
to	NULL
evaluate	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
the	NULL
cell	NULL
model	NULL
in	NULL
light	NULL
of	NULL
findings	NULL
with	NULL
primary	NULL
monocytic	NULL
cells	NULL
.	NULL

Given	NULL
the	NULL
abundant	NULL
regulatory	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
whether	NULL
developmentally	NULL
regulated	NULL
or	NULL
induced	NULL
by	NULL
HIV	NULL
infection	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
provides	NULL
a	NULL
range	NULL
of	NULL
potent	NULL
signals	NULL
for	NULL
stimulation	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
and	NULL
cytokine	NULL
activation	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
Tom	NULL
Rado	NULL
,	NULL
University	NULL
of	NULL
Alabama	NULL
,	NULL
for	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
PLB-985	NULL
cells	NULL
.	NULL

We	NULL
thank	NULL
Rhona	NULL
Rosenzweig	NULL
for	NULL
typing	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
research	NULL
grants	NULL
from	NULL
Health	NULL
and	NULL
Welfare	NULL
Canada	NULL
(	NULL
6605-3954-AIDS	NULL
and	NULL
6605-3815-AIDS	NULL
)	NULL
and	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
of	NULL
Canada	NULL
(	NULL
MT-9295	NULL
and	NULL
MT-9625	NULL
)	NULL
to	NULL
J.	NULL
Hiscott	NULL
and	NULL
M.	NULL
A.	NULL
Wainberg	NULL
.	NULL

A.	NULL
Roulston	NULL
is	NULL
the	NULL
recipient	NULL
of	NULL
a	NULL
studentship	NULL
from	NULL
Fonds	NULL
pour	NULL
la	NULL
formation	NULL
de	NULL
chercheurs	NULL
et	NULL
l'aide	NULL
a	NULL
la	NULL
recherche	NULL
(	NULL
FCAR	NULL
)	NULL
.	NULL

J.	NULL
Hiscott	NULL
is	NULL
the	NULL
recipient	NULL
of	NULL
a	NULL
senior	NULL
chercheur	NULL
boursier	NULL
from	NULL
the	NULL
Fonds	NULL
de	NULL
la	NULL
Recherche	NULL
en	NULL
Santé	NULL
du	NULL
Québec	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
John	NULL
Hiscott	NULL
,	NULL
Ph.D	NULL
,	NULL
Lady	NULL
Davis	NULL
Institute	NULL
for	NULL
Medical	NULL
Research	NULL
,	NULL
Sir	NULL
Mortimer	NULL
B.	NULL
Davis	NULL
-	NULL
Jewish	NULL
General	NULL
Hospital	NULL
,	NULL
3755	NULL
Cote	NULL
Ste	NULL
.	NULL

Catherine	NULL
Road	NULL
,	NULL
Montreal	NULL
,	NULL
Quebec	NULL
H3T	NULL
1E2	NULL
,	NULL
Canada	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
6	NULL
August	NULL
1991	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
1	NULL
November	NULL
1991	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Fauci	NULL
,	NULL
A.S.	NULL
1988	NULL
.	NULL

The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
:	NULL
infec-tivity	NULL
and	NULL
mechanisms	NULL
of	NULL
pathogenesis	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

239:617	NULL
.	NULL

2	NULL
.	NULL

Folks	NULL
,	NULL
R.M.S	NULL
.	NULL

,	NULL
SW.	NULL
Kessler	NULL
,	NULL
J.M	NULL
.	NULL

Orenstein	NULL
,	NULL
J.S	NULL
.	NULL

Justement	NULL
,	NULL
E.S	NULL
.	NULL

Jaffe	NULL
,	NULL
and	NULL
A.S.	NULL
Fauci	NULL
.	NULL

1988	NULL
.	NULL

Infection	NULL
and	NULL
replication	NULL
of	NULL
HIV-1	NULL
in	NULL
purified	NULL
progenitor	NULL
cells	NULL
of	NULL
normal	NULL
human	NULL
bone	NULL
marrow	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

242:919	NULL
.	NULL

3	NULL
.	NULL

Meltzer	NULL
,	NULL
M.S	NULL
.	NULL

,	NULL
D.R	NULL
.	NULL

Skilman	NULL
,	NULL
P.J	NULL
.	NULL

Gamatos	NULL
,	NULL
D.C.	NULL
Kalter	NULL
,	NULL
and	NULL
H.E	NULL
.	NULL

Gendelman	NULL
.	NULL

1990	NULL
.	NULL

Role	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8:169	NULL
.	NULL

4	NULL
.	NULL

Mann	NULL
,	NULL
D.L	NULL
.	NULL

,	NULL
S.	NULL
Gartner	NULL
,	NULL
F.	NULL
Le	NULL
Sane	NULL
,	NULL
H.	NULL
Buchow	NULL
,	NULL
and	NULL
M.	NULL
Po-povic	NULL
.	NULL

1990	NULL
.	NULL

HIV-1	NULL
transmission	NULL
and	NULL
function	NULL
of	NULL
virus-infected	NULL
monocytes/macrophages	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

144:2152	NULL
.	NULL

5	NULL
.	NULL

Roy	NULL
,	NULL
S.	NULL
,	NULL
L.	NULL
Fitz-Gibbon	NULL
,	NULL
L.	NULL
Poulin	NULL
,	NULL
and	NULL
M.A	NULL
.	NULL

Wainberg	NULL
.	NULL

1988	NULL
.	NULL

Infection	NULL
of	NULL
human	NULL
monocytes/macrophages	NULL
by	NULL
HIV-1	NULL
:	NULL
effect	NULL
on	NULL
secretion	NULL
of	NULL
IL-1	NULL
activity	NULL
.	NULL

Immunology	NULL
.	NULL

64:233	NULL
.	NULL

6	NULL
.	NULL

Smith	NULL
,	NULL
P.D	NULL
.	NULL

,	NULL
K.	NULL
Ohura	NULL
,	NULL
H.	NULL
Masur	NULL
,	NULL
H.C.	NULL
Lane	NULL
,	NULL
A.S.	NULL
Fauci	NULL
,	NULL
and	NULL
S.M	NULL
.	NULL

Wahl	NULL
.	NULL

1984	NULL
.	NULL

Monocyte	NULL
function	NULL
in	NULL
the	NULL
acquired	NULL
immune	NULL
761	NULL
Roulston	NULL
et	NULL
al	NULL
.	NULL

deficiency	NULL
syndrome	NULL
.	NULL

Defective	NULL
chemotaxis	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

74:2121	NULL
.	NULL

7	NULL
.	NULL

Arai	NULL
,	NULL
K.I	NULL
.	NULL

,	NULL
F.	NULL
Lee	NULL
,	NULL
A.	NULL
Miyajima	NULL
,	NULL
S.	NULL
Miyatake	NULL
,	NULL
N.	NULL
Arai	NULL
,	NULL
and	NULL
T.	NULL
Yokota	NULL
.	NULL

1990	NULL
.	NULL

Cytokines	NULL
:	NULL
coordinates	NULL
of	NULL
immune	NULL
and	NULL
inflammatory	NULL
responses	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

59:783	NULL
.	NULL

8	NULL
.	NULL

Duh	NULL
,	NULL
EJ	NULL
.	NULL

,	NULL
W.	NULL
Maury	NULL
,	NULL
TM	NULL
.	NULL

Folks	NULL
,	NULL
A.S.	NULL
Fauci	NULL
,	NULL
and	NULL
A.B	NULL
.	NULL

Rabson	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
x	NULL
activates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
through	NULL
induction	NULL
of	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:5974	NULL
.	NULL

9	NULL
.	NULL

D'Addario	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Roulston	NULL
,	NULL
M.A	NULL
.	NULL

Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1990	NULL
.	NULL

Coordinate	NULL
enhancement	NULL
of	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1-infected	NULL
promonocytic	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:6080	NULL
.	NULL

10	NULL
.	NULL

Folks	NULL
,	NULL
TM	NULL
.	NULL

,	NULL
K.A	NULL
.	NULL

Clouse	NULL
,	NULL
J.S	NULL
.	NULL

Justement	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
E.	NULL
Duh	NULL
,	NULL
J.H	NULL
.	NULL

Kehrl	NULL
,	NULL
and	NULL
A.S.	NULL
Fauci	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
&	NULL
induces	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
T-cell	NULL
clone	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:2365	NULL
.	NULL

11	NULL
.	NULL

Folks	NULL
,	NULL
T.M	NULL
.	NULL

,	NULL
J.S	NULL
.	NULL

Justement	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
C.A	NULL
.	NULL

Dinarello	NULL
,	NULL
and	NULL
12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

A.S.	NULL
Fauci	NULL
.	NULL

1987	NULL
.	NULL

Cytokine	NULL
induced	NULL
expression	NULL
of	NULL
HIV-1	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
promonocytic	NULL
cell	NULL
line	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

238:800	NULL
.	NULL

Gendelman	NULL
,	NULL
H.E	NULL
.	NULL

,	NULL
R.M	NULL
.	NULL

Friedman	NULL
,	NULL
S.	NULL
Joe	NULL
,	NULL
L.M	NULL
.	NULL

Baca	NULL
,	NULL
J.A	NULL
.	NULL

Turpin	NULL
,	NULL
G.	NULL
Dveksler	NULL
,	NULL
M.S	NULL
.	NULL

Meltzer	NULL
,	NULL
and	NULL
C.	NULL
Dieffenbach	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
selective	NULL
defect	NULL
of	NULL
interferon	NULL
x	NULL
production	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus-infected	NULL
monocytes	NULL
.	NULL

J.	NULL
Exp	NULL
Med	NULL
.	NULL

172	NULL
:	NULL
1433	NULL
.	NULL

Molina	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
DT	NULL
.	NULL

Scadden	NULL
,	NULL
C.	NULL
Amirault	NULL
,	NULL
A.	NULL
Woon	NULL
,	NULL
E.	NULL
Van-nier	NULL
,	NULL
C.A	NULL
.	NULL

Dinarello	NULL
,	NULL
and	NULL
J.F	NULL
.	NULL

Groopman	NULL
.	NULL

1990	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
does	NULL
not	NULL
induce	NULL
interleukin	NULL
1	NULL
,	NULL
interleukin	NULL
6	NULL
,	NULL
or	NULL
tumor	NULL
necrosis	NULL
factor	NULL
in	NULL
mononuclear	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2901	NULL
.	NULL

Molina	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
R.	NULL
Schindler	NULL
,	NULL
R.	NULL
Ferriani	NULL
,	NULL
M.	NULL
Sakaguchi	NULL
,	NULL
E.	NULL
Van-nier	NULL
,	NULL
C.A	NULL
.	NULL

Dinarello	NULL
,	NULL
and	NULL
J.F	NULL
.	NULL

Groopman	NULL
.	NULL

1990	NULL
.	NULL

Production	NULL
of	NULL
cytokines	NULL
by	NULL
peripheral	NULL
blood	NULL
monocytes/macrophages	NULL
infected	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

161:888	NULL
.	NULL

Voth	NULL
,	NULL
R.	NULL
,	NULL
S.	NULL
Rossol	NULL
,	NULL
K.	NULL
Klein	NULL
,	NULL
G.	NULL
Hess	NULL
,	NULL
K.	NULL
Schutt	NULL
,	NULL
H.	NULL
Schroder	NULL
,	NULL
K.	NULL
Buschfelde	NULL
,	NULL
and	NULL
W.	NULL
Muller	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
gene	NULL
expression	NULL
of	NULL
IFN-a	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
&	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
AIDS	NULL
related	NULL
complex	NULL
and	NULL
AIDS	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

140:120	NULL
.	NULL

Vyakarnam	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Mataer	NULL
,	NULL
A	NULL
.	NULL

Meager	NULL
,	NULL
G.	NULL
Kelly	NULL
,	NULL
B.	NULL
Stanley	NULL
,	NULL
I.	NULL
Weller	NULL
,	NULL
and	NULL
P.	NULL
Beverley	NULL
.	NULL

1991	NULL
.	NULL

Altered	NULL
production	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
and	NULL
beta	NULL
and	NULL
interferon	NULL
gamma	NULL
by	NULL
HIV	NULL
infected	NULL
individuals	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
Immunol	NULL
.	NULL

84:109	NULL
.	NULL

Yamato	NULL
,	NULL
K.	NULL
,	NULL
Z.	NULL
El-Hajjaoui	NULL
,	NULL
K.	NULL
Simon	NULL
,	NULL
and	NULL
H.P	NULL
.	NULL

Koeffler	NULL
.	NULL

1990	NULL
.	NULL

Modulation	NULL
of	NULL
interleukin	NULL
13	NULL
RNA	NULL
in	NULL
monocytic	NULL
cells	NULL
infected	NULL
with	NULL
human	NULL
immuno-deficiency	NULL
virus	NULL
1	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

86:1109	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.J	NULL
.	NULL

Nabel	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
&	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
KB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:2336	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
E.	NULL
Duh	NULL
,	NULL
W.C.	NULL
Timmer	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
J.S	NULL
.	NULL

Justement	NULL
,	NULL
S.	NULL
Stanley	NULL
,	NULL
and	NULL
A.S.	NULL
Fauci	NULL
.	NULL

1990	NULL
.	NULL

Interleukin	NULL
6	NULL
induces	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
expression	NULL
in	NULL
infected	NULL
monocytic	NULL
cells	NULL
alone	NULL
and	NULL
in	NULL
synergy	NULL
with	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
by	NULL
transcriptional	NULL
and	NULL
post-transcriptional	NULL
mechanisms	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:151	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
J.S	NULL
.	NULL

Justement	NULL
,	NULL
J.H	NULL
.	NULL

Kerh	NULL
]	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
S.	NULL
Stanley	NULL
,	NULL
and	NULL
A.S.	NULL
Fauci	NULL
.	NULL

1990	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
&	NULL
functions	NULL
in	NULL
an	NULL
autocrine	NULL
manner	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
expression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

87:782	NULL
.	NULL

Israel	NULL
,	NULL
N.	NULL
,	NULL
U.	NULL
Hazan	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
A.	NULL
Munier	NULL
,	NULL
F.	NULL
Arenzana-Seisdedos	NULL
,	NULL
F.	NULL
Bachelerie	NULL
,	NULL
A.	NULL
Israel	NULL
,	NULL
and	NULL
J.L	NULL
.	NULL

Virelizier	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
stimulates	NULL
transcription	NULL
of	NULL
HIV-1	NULL
in	NULL
human	NULL
T-lymphocytes	NULL
independently	NULL
and	NULL
synergistically	NULL
with	NULL
mitogens	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143:3956	NULL
.	NULL

Baeuerle	NULL
,	NULL
PA.	NULL
1991	NULL
.	NULL

The	NULL
inducible	NULL
transcription	NULL
activator	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
regulation	NULL
by	NULL
distinct	NULL
protein	NULL
subunits	NULL
.	NULL

Biockem	NULL
.	NULL

Bio-phys	NULL
.	NULL

Acta	NULL
.	NULL

1072:63	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
'T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

326:711	NULL
.	NULL

Lacoste	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
D'Addario	NULL
,	NULL
A.	NULL
Roulston	NULL
,	NULL
M.A	NULL
.	NULL

Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1990	NULL
.	NULL

Cell-specific	NULL
differences	NULL
in	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
regulatory	NULL
elements	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
and	NULL
beta	NULL
interferon	NULL
promoters	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:4726	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.A	NULL
.	NULL

,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
65-kD	NULL
subunit	NULL
of	NULL
active	NULL
NF-KB	NULL
is	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
by	NULL
IB	NULL
.	NULL

Genes	NULL
762	NULL
26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

&	NULL
Dev	NULL
.	NULL

3:1689	NULL
.	NULL

Urban	NULL
,	NULL
M.B	NULL
.	NULL

,	NULL
and	NULL
P.	NULL
Baeuerle	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
p50	NULL
and	NULL
p65	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
recognition	NULL
of	NULL
cognate	NULL
sequences	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

3:279	NULL
.	NULL

Ballard	NULL
,	NULL
W.D	NULL
.	NULL

,	NULL
W.H	NULL
.	NULL

Walker	NULL
,	NULL
S.	NULL
Doerre	NULL
,	NULL
P.	NULL
Sista	NULL
,	NULL
L.A.	NULL
Molitar	NULL
,	NULL
E.P	NULL
.	NULL

Dixon	NULL
,	NULL
N.I	NULL
.	NULL

Peffer	NULL
,	NULL
M.	NULL
Hannick	NULL
,	NULL
and	NULL
W.C.	NULL
Greene	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
v-rel	NULL
oncogene	NULL
encodes	NULL
a	NULL
«	NULL
B	NULL
enhancer	NULL
binding	NULL
protein	NULL
that	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
function	NULL
.	NULL

Cell	NULL
.	NULL

63:803	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
A.M.	NULL
Gifford	NULL
,	NULL
L.R	NULL
.	NULL

Riviere	NULL
,	NULL
P.	NULL
Tempst	NULL
,	NULL
G.P	NULL
.	NULL

Nolan	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
p50	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
homology	NULL
to	NULL
rel	NULL
and	NULL
dorsal	NULL
.	NULL

Cell	NULL
.	NULL

62:1019	NULL
.	NULL

Inoue	NULL
,	NULL
J.-L.	NULL
,	NULL
L.D	NULL
.	NULL

Kerr	NULL
,	NULL
L.J	NULL
.	NULL

Ransone	NULL
,	NULL
E.	NULL
Bengal	NULL
,	NULL
T.	NULL
Hunter	NULL
,	NULL
and	NULL
I.M	NULL
.	NULL

Verma	NULL
.	NULL

1991.	NULL
c-rel	NULL
activates	NULL
but	NULL
v-rel	NULL
suppresses	NULL
transcription	NULL
from	NULL
KB	NULL
sites	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

88:3715	NULL
.	NULL

Kieran	NULL
,	NULL
M.	NULL
,	NULL
V.	NULL
Blank	NULL
,	NULL
F.	NULL
Logeat	NULL
,	NULL
J.	NULL
Vandekerckhove	NULL
,	NULL
F.	NULL
Lott-speich	NULL
,	NULL
Q	NULL
.	NULL

Le	NULL
Bail	NULL
,	NULL
M.B	NULL
.	NULL

Urban	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
P.A	NULL
.	NULL

Baeuerle	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
NF-KB	NULL
is	NULL
identical	NULL
to	NULL
factor	NULL
KBF1	NULL
and	NULL
homologous	NULL
to	NULL
the	NULL
rel	NULL
oncogene	NULL
product	NULL
.	NULL

Cell	NULL
.	NULL

62:1007	NULL
.	NULL

Nolan	NULL
,	NULL
GP	NULL
.	NULL

,	NULL
S.	NULL
Ghosh	NULL
,	NULL
H.-C.	NULL
Liou	NULL
,	NULL
P.	NULL
Tempst	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1991	NULL
.	NULL

DNA	NULL
binding	NULL
and	NULL
IB	NULL
inhibition	NULL
of	NULL
the	NULL
cloned	NULL
p65	NULL
subunit	NULL
of	NULL
NF-KB	NULL
,	NULL
a	NULL
rel	NULL
related	NULL
polypeptide	NULL
.	NULL

Cell	NULL
.	NULL

64:961	NULL
.	NULL

Molitor	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
W.H	NULL
.	NULL

Walker	NULL
,	NULL
S.	NULL
Doerre	NULL
,	NULL
DW	NULL
.	NULL

Ballard	NULL
,	NULL
and	NULL
WC	NULL
.	NULL

Greene	NULL
.	NULL

1990.	NULL
a	NULL
family	NULL
of	NULL
inducible	NULL
and	NULL
differentially	NULL
expressed	NULL
enhancer-binding	NULL
proteins	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

$	NULL
7:10028	NULL
.	NULL

Tucker	NULL
,	NULL
K.A	NULL
.	NULL

,	NULL
M.B	NULL
.	NULL

Lilly	NULL
,	NULL
L.	NULL
Heck	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
T.A	NULL
.	NULL

Rado	NULL
.	NULL

1987	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
new	NULL
diploid	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
PLB-985	NULL
)	NULL
with	NULL
granulocytic	NULL
and	NULL
monocytic	NULL
differentiation	NULL
ca-pacity	NULL
.	NULL

Blood	NULL
.	NULL

70:372	NULL
.	NULL

Dubreuil	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Sportza	NULL
,	NULL
M.	NULL
D'Addario	NULL
,	NULL
J.	NULL
Lacoste	NULL
,	NULL
R.	NULL
Rooke	NULL
,	NULL
M.A	NULL
.	NULL

Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1990	NULL
.	NULL

Inhibition	NULL
of	NULL
HIV-1	NULL
transmission	NULL
by	NULL
interferon	NULL
and	NULL
3-	NULL
Azido-3'-deoxythyimidine	NULL
during	NULL
de	NULL
novo	NULL
infection	NULL
of	NULL
promonocytic	NULL
cells	NULL
.	NULL

Virology	NULL
.	NULL

179:388	NULL
.	NULL

Chomczynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
N.	NULL
Sacchi	NULL
.	NULL

1987	NULL
.	NULL

Single	NULL
step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
acid	NULL
guanidinium	NULL
thiocyanate-phenol-chloroform	NULL
extraction	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162:150	NULL
.	NULL

Lacoste	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
Cohen	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1991	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
stably	NULL
expressing	NULL
the	NULL
Tax	NULL
protein	NULL
of	NULL
HTLV-1	NULL
.	NULL

Virology	NULL
.	NULL

184:553	NULL
.	NULL

Gonda	NULL
,	NULL
T.J.	NULL
,	NULL
and	NULL
D.	NULL
Metcalf	NULL
.	NULL

1984	NULL
.	NULL

Expression	NULL
of	NULL
myb	NULL
,	NULL
myc	NULL
and	NULL
fos	NULL
proto-oncogenes	NULL
during	NULL
the	NULL
differentiation	NULL
of	NULL
a	NULL
murine	NULL
myeloid	NULL
leukemia	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

310:249	NULL
.	NULL

Sariban	NULL
,	NULL
E.	NULL
,	NULL
T.	NULL
Mitchell	NULL
,	NULL
and	NULL
D.	NULL
Kufe	NULL
.	NULL

1985	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
c-fms	NULL
proto-oncogene	NULL
during	NULL
human	NULL
monocytic	NULL
differentiation	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

316:64	NULL
.	NULL

Griffin	NULL
,	NULL
G.E	NULL
.	NULL

,	NULL
K.	NULL
Leung	NULL
,	NULL
T.M	NULL
.	NULL

Folks	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.J	NULL
.	NULL

Nabel	NULL
.	NULL

1989	NULL
.	NULL

Activation	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
during	NULL
monocyte	NULL
differentiation	NULL
by	NULL
induction	NULL
of	NULL
NF-kB	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

339:70	NULL
.	NULL

Suzan	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
Salaun	NULL
,	NULL
C.	NULL
Neuvent	NULL
,	NULL
B.	NULL
Spire	NULL
,	NULL
I.	NULL
Hirsch	NULL
,	NULL
P.	NULL
Le	NULL
«	NULL
Bouteiller	NULL
,	NULL
G.	NULL
Querat	NULL
,	NULL
and	NULL
J.	NULL
Sire	NULL
.	NULL

1991	NULL
.	NULL

Induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
during	NULL
monocyte	NULL
differentiation	NULL
by	NULL
HIV	NULL
type	NULL
1	NULL
infection	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:377	NULL
.	NULL

Folks	NULL
,	NULL
T.M	NULL
.	NULL

,	NULL
J.	NULL
Justement	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
S.	NULL
Schnittman	NULL
,	NULL
J.	NULL
Orenstein	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
and	NULL
A.	NULL
Fauci	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
pro-monocyte	NULL
clone	NULL
chronically	NULL
infected	NULL
with	NULL
HIV	NULL
and	NULL
inducible	NULL
by	NULL
PMA	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

140:1117	NULL
.	NULL

Cohen	NULL
,	NULL
L.	NULL
,	NULL
J.	NULL
Lacoste	NULL
,	NULL
M.	NULL
Parniak	NULL
,	NULL
L.	NULL
Daigneault	NULL
,	NULL
D.	NULL
Skup	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1991	NULL
.	NULL

Stimulation	NULL
of	NULL
interferon	NULL
3	NULL
transcription	NULL
in	NULL
vitro	NULL
by	NULL
purified	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
a	NULL
novel	NULL
TH	NULL
protein	NULL
.	NULL

Cell	NULL
Growth	NULL
&	NULL
Differ	NULL
2:323	NULL
.	NULL

Baldwin	NULL
,	NULL
A.S.	NULL
,	NULL
Jr.	NULL
,	NULL
J.C.	NULL
Azizkhan	NULL
,	NULL
D.E	NULL
.	NULL

Jensen	NULL
,	NULL
A.A.	NULL
Beg	NULL
,	NULL
and	NULL
L.R	NULL
.	NULL

Coodly	NULL
.	NULL

1991	NULL
.	NULL

Induction	NULL
of	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
activity	NULL
NF-	NULL
«	NULL
B	NULL
Activity	NULL
in	NULL
HIV-1-infected	NULL
Monocytic	NULL
Cells	NULL
45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48.	NULL
during	NULL
the	NULL
Go-to-G1	NULL
transition	NULL
in	NULL
mouse	NULL
fibroblasts	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:4943.	NULL
.	NULL

Haskill	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
Beg	NULL
,	NULL
H.	NULL
Tompkins	NULL
,	NULL
J.	NULL
Morris	NULL
,	NULL
A.	NULL
Yurochko	NULL
,	NULL
A.	NULL
Sampson-Johannes	NULL
,	NULL
K.	NULL
Mondal	NULL
,	NULL
P.	NULL
Ralph	NULL
,	NULL
and	NULL
A.	NULL
Baldwin	NULL
.	NULL

1991	NULL
.	NULL

Characterization	NULL
of	NULL
an	NULL
immediate-early	NULL
gene	NULL
induced	NULL
in	NULL
adherent	NULL
monocytes	NULL
that	NULL
encodes	NULL
IxB-like	NULL
activity	NULL
.	NULL

Cell	NULL
.	NULL

65:1281	NULL
.	NULL

Bours	NULL
,	NULL
V.	NULL
,	NULL
J.	NULL
Villalobos	NULL
,	NULL
P.	NULL
Burd	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1990	NULL
.	NULL

Cloning	NULL
of	NULL
a	NULL
mitogen	NULL
inducible	NULL
gene	NULL
encoding	NULL
a	NULL
«	NULL
B	NULL
DNA-binding	NULL
protein	NULL
with	NULL
homology	NULL
to	NULL
the	NULL
rel	NULL
oncogene	NULL
and	NULL
to	NULL
cell	NULL
cycle	NULL
motifs	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

348:76	NULL
.	NULL

Riviers	NULL
,	NULL
Y.	NULL
,	NULL
V.	NULL
Blank	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1991	NULL
.	NULL

Processing	NULL
of	NULL
the	NULL
precursor	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
HIV-1	NULL
protease	NULL
during	NULL
acute	NULL
infection	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

350:625	NULL
.	NULL

Maniatis	NULL
,	NULL
T.	NULL
,	NULL
L.-A	NULL
.	NULL

Whittenmore	NULL
,	NULL
W.	NULL
Du	NULL
,	NULL
C.-M	NULL
.	NULL

Fan	NULL
,	NULL
A.D.	NULL
Keller	NULL
,	NULL
V.J	NULL
.	NULL

Palombella	NULL
,	NULL
and	NULL
D.	NULL
Thanos	NULL
.	NULL

1991	NULL
.	NULL

Positive	NULL
and	NULL
negative	NULL
control	NULL
of	NULL
human	NULL
interferon	NULL
3	NULL
gene	NULL
expression	NULL
.	NULL

In	NULL
Transcriptional	NULL
Regulation	NULL
.	NULL

K.R	NULL
.	NULL

Yamamoto	NULL
and	NULL
S.L	NULL
.	NULL

McKnight	NULL
,	NULL
editors	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratories	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
.	NULL

Eckner	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
M.	NULL
Birnstiel	NULL
.	NULL

1989	NULL
.	NULL

Cloning	NULL
of	NULL
cDNAs	NULL
coding	NULL
for	NULL
human	NULL
HMG	NULL
I	NULL
and	NULL
HMG	NULL
Y	NULL
proteins	NULL
:	NULL
both	NULL
are	NULL
capable	NULL
763	NULL
Roulston	NULL
et	NULL
al	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52.	NULL
of	NULL
binding	NULL
to	NULL
the	NULL
octamer	NULL
sequence	NULL
motif	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:5947	NULL
.	NULL

Solomon	NULL
,	NULL
M.	NULL
,	NULL
F.	NULL
Strauss	NULL
,	NULL
and	NULL
A.	NULL
Varshavsky	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
mammalian	NULL
high	NULL
mobility	NULL
group	NULL
protein	NULL
recognizes	NULL
any	NULL
stretch	NULL
of	NULL
six	NULL
AT	NULL
base	NULL
pairs	NULL
in	NULL
duplex	NULL
DNA	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

83:1276	NULL
.	NULL

Goodwin	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
PN	NULL
.	NULL

Cockerill	NULL
,	NULL
S.	NULL
Kellan	NULL
,	NULL
and	NULL
C.A	NULL
.	NULL

Wright	NULL
.	NULL

1985	NULL
.	NULL

Fractionation	NULL
by	NULL
high	NULL
performance	NULL
liquid	NULL
chromatog-raphy	NULL
of	NULL
the	NULL
low	NULL
molecular	NULL
mass	NULL
high	NULL
mobility	NULL
group	NULL
(	NULL
HMG	NULL
)	NULL
chromosomal	NULL
proteins	NULL
present	NULL
in	NULL
proliferating	NULL
rat	NULL
cells	NULL
and	NULL
an	NULL
investigation	NULL
of	NULL
the	NULL
HMG	NULL
proteins	NULL
present	NULL
in	NULL
virus	NULL
transformed	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

149:47	NULL
.	NULL

Vartianen	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
Palvimo	NULL
,	NULL
A.	NULL
Mahonen	NULL
,	NULL
A.	NULL
Linnala-Kankkunen	NULL
,	NULL
and	NULL
P.H	NULL
.	NULL

Maenpaa	NULL
.	NULL

1988	NULL
.	NULL

Selective	NULL
decrease	NULL
in	NULL
low-Mr	NULL
HMG	NULL
proteins	NULL
HMG	NULL
I	NULL
and	NULL
HMG	NULL
Y	NULL
during	NULL
differentiation	NULL
of	NULL
mouse	NULL
teratocarcinoma	NULL
cells	NULL
.	NULL

FEBS	NULL
(	NULL
Fed	NULL
.	NULL

Eur	NULL
.	NULL

Biochem	NULL
.	NULL

Soc	NULL
.	NULL
)	NULL

Lett	NULL
.	NULL

228:45	NULL
.	NULL

Schmid	NULL
,	NULL
R.M	NULL
.	NULL

,	NULL
N.D.	NULL
Perkins	NULL
,	NULL
C.S	NULL
.	NULL

Duckett	NULL
,	NULL
PC	NULL
.	NULL

Andrews	NULL
,	NULL
and	NULL
G.J	NULL
.	NULL

Nabel	NULL
.	NULL

19914	NULL
.	NULL

Cloning	NULL
of	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
subunit	NULL
which	NULL
stimulates	NULL
HIV	NULL
transcription	NULL
in	NULL
synergy	NULL
with	NULL
p65	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

352:733	NULL
.	NULL

